# 2026年1月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 靶向微生物组驱动的表观遗传修饰：乳腺癌治疗的新前沿。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580778)
**期刊：** Clinical epigenetics
**PMID：** 41580778
**DOI：** 10.1186/s13148-025-02046-0

### 第一部分 原文与翻译

**英文原标题：** Targeting microbiome-driven epigenetic modifications: a new frontier in breast cancer treatment.

> **英文摘要：**
> Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant heterogeneity in its development and treatment response. Recent advances in understanding the roles of the microbiome and epigenetic regulation have opened new avenues for addressing the complexities of breast cancer progression and therapeutic resistance. This review explores the intricate relationship between the gut and intratumoral microbiomes and epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNAs. Specifically, we examine how microbial metabolites, particularly short-chain fatty acids (SCFAs), regulate gene expression via epigenetic mechanisms, influencing tumor growth, metastasis, and treatment response. The impact of metabolic diseases, including obesity and type 2 diabetes mellitus (T2DM), on breast cancer risk through microbiome-mediated epigenetic changes is also discussed. Furthermore, the review highlights emerging therapeutic strategies that integrate microbiome modulation with epigenetic therapies, including the use of probiotics, dietary interventions, and fecal microbiota transplantation (FMT), as well as DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors. These innovative approaches hold promise for overcoming treatment resistance and improving clinical outcomes in breast cancer patients. Future research should focus on elucidating the molecular pathways through which the microbiome influences epigenetic regulation and developing personalized, microbiome-targeted therapies that enhance the efficacy of existing treatments. By targeting both the genetic and epigenetic drivers of breast cancer, microbiome-based interventions represent a novel frontier in the fight against this challenging disease.

> **中文摘要：**
> 乳腺癌仍然是全球女性发病和死亡的主要原因，其发生发展及治疗反应具有显著的异质性。近期在理解微生物组和表观遗传调控作用方面的进展，为解决乳腺癌进展和治疗抵抗的复杂性开辟了新途径。本综述探讨了肠道及肿瘤内微生物组与表观遗传修饰（如DNA甲基化、组蛋白修饰和非编码RNA）之间的复杂关系。具体而言，我们研究了微生物代谢物，特别是短链脂肪酸（SCFAs），如何通过表观遗传机制调控基因表达，从而影响肿瘤生长、转移和治疗反应。文章还讨论了代谢性疾病（包括肥胖和2型糖尿病）如何通过微生物组介导的表观遗传变化影响乳腺癌风险。此外，本综述重点介绍了整合微生物组调控与表观遗传疗法的新兴治疗策略，包括使用益生菌、饮食干预和粪便微生物群移植（FMT），以及DNA甲基转移酶（DNMT）抑制剂和组蛋白去乙酰化酶（HDAC）抑制剂。这些创新方法有望克服治疗抵抗并改善乳腺癌患者的临床结局。未来的研究应侧重于阐明微生物组影响表观遗传调控的分子通路，并开发能够增强现有治疗效果的、个性化的、靶向微生物组的疗法。通过同时靶向乳腺癌的遗传和表观遗传驱动因素，基于微生物组的干预措施代表了对抗这一棘手疾病的新前沿。

### 第二部分 AI 大师评价

本文献是一篇综述，核心目的是探讨微生物组通过表观遗传机制影响乳腺癌发生发展和治疗反应，并展望整合两者的新型治疗策略。方法上，文章系统梳理了微生物代谢物（如SCFAs）调控DNA甲基化、组蛋白修饰等表观遗传途径的证据，并分析了代谢疾病通过该途径影响乳腺癌风险的关联。其创新性在于将“微生物组-表观遗传”轴确立为一个关键调控网络，并提出了整合益生菌、FMT等微生物干预与DNMT/HDAC抑制剂等表观遗传药物的联合治疗新范式。局限性在于，作为一篇综述，其提出的分子通路和联合策略仍需大量基础与临床研究来验证其具体机制和疗效。

---

## 2. 单细胞转录组学揭示RNF130介导的TNF-α通路激活及乌药碱与紫杉醇在乳腺癌中的协同作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580768)
**期刊：** Clinical epigenetics
**PMID：** 41580768
**DOI：** 10.1186/s13148-026-02057-5

### 第一部分 原文与翻译

**英文原标题：** Single-cell transcriptomics uncover RNF130-mediated TNF-α pathway activation and worenine synergy with paclitaxel in breast cancer.

> **英文摘要：**
> BACKGROUND: Triple-negative breast cancer (TNBC) is distinguished by high invasiveness and a tendency for recurrence. Recent studies have suggested that E3 ubiquitin ligases play a crucial role in the initiation and progression of various tumors. However, there is still an absence of systematic understanding regarding the specific function and molecular mechanisms of its member gene RNF130 in TNBC. METHODS: This study conducted a comprehensive analysis of large-scale transcriptomic data from databases such as TCGA and GEO. Additionally, single-cell RNA sequencing data from multiple breast cancer samples and their liver metastases were analyzed to evaluate the expression pattern, prognostic significance, and potential regulatory role of RNF130 in the tumor microenvironment. The effects of RNF130 on breast cancer cell proliferation, apoptosis, and chemotherapy sensitivity were explored through in vitro cell experiments and in vivo mouse models. Furthermore, the study screened and evaluated the targeted inhibitory effect of the Traditional Chinese Medicine active component Worenine on RNF130, as well as its combined therapeutic effect with paclitaxel. RESULTS: The findings indicated that RNF130 was notably overexpressed in breast cancer tissues and associated with unfavorable patient survival outcomes. Single-cell transcriptomic analysis revealed that RNF130 was predominantly enriched in恶性上皮细胞群 and closely associated with tumor immune evasion phenotypes. RNF130 knockdown inhibited proliferation, induced apoptosis, reduced TNF-α pathway activation, and enhanced sensitivity to paclitaxel, whereas RNF130 overexpression exerted the opposite effects. Co-culture experiments further demonstrated that RNF130 depletion promoted M1 macrophage polarization while control cells induced M2-like phenotypes. Additionally, Worenine downregulated RNF130 expression and displayed a synergistic inhibitory effect with paclitaxel. CONCLUSION: This study identifies RNF130 as a critical mediator of TNBC progression that regulates tumor growth, apoptosis, immune evasion, and metabolic reprogramming, partly through activation of the TNF-α signaling pathway. Furthermore, Worenine was found to reduce RNF130 expression and enhance the antitumor effect of paclitaxel, suggesting its potential utility in combination therapy for TNBC. These findings provide mechanistic insights into RNF130-driven malignancy and offer a foundation for developing future therapeutic strategies.

> **中文摘要：**
> 背景：三阴性乳腺癌（TNBC）具有高侵袭性和易复发的特点。近期研究表明，E3泛素连接酶在多种肿瘤的发生发展中起着关键作用。然而，对于其成员基因RNF130在TNBC中的具体功能和分子机制，目前仍缺乏系统性的认识。方法：本研究对来自TCGA和GEO等数据库的大规模转录组数据进行了综合分析。此外，分析了来自多个乳腺癌样本及其肝转移灶的单细胞RNA测序数据，以评估RNF130在肿瘤微环境中的表达模式、预后意义及潜在调控作用。通过体外细胞实验和体内小鼠模型，探讨了RNF130对乳腺癌细胞增殖、凋亡和化疗敏感性的影响。进一步地，本研究筛选并评估了中药活性成分乌药碱对RNF130的靶向抑制作用，及其与紫杉醇的联合治疗效果。结果：研究结果表明，RNF130在乳腺癌组织中显著过表达，并与不良的患者生存结局相关。单细胞转录组分析显示，RNF130主要富集于恶性上皮细胞群，并与肿瘤免疫逃逸表型密切相关。敲低RNF130抑制了细胞增殖、诱导了细胞凋亡、降低了TNF-α通路活性并增强了对紫杉醇的敏感性，而过表达RNF130则产生相反的效果。共培养实验进一步证明，RNF130的耗竭促进了M1巨噬细胞极化，而对照细胞则诱导了M2样表型。此外，乌药碱下调了RNF130的表达，并显示出与紫杉醇的协同抑制作用。结论：本研究确定RNF130是TNBC进展的关键介质，它部分通过激活TNF-α信号通路来调控肿瘤生长、凋亡、免疫逃逸和代谢重编程。此外，研究发现乌药碱能够降低RNF130表达并增强紫杉醇的抗肿瘤作用，提示其在TNBC联合治疗中的潜在应用价值。这些发现为理解RNF130驱动的恶性肿瘤提供了机制性见解，并为开发未来的治疗策略奠定了基础。

### 第二部分 AI 大师评价

本研究旨在系统阐明E3泛素连接酶RNF130在三阴性乳腺癌中的功能机制及治疗潜力。研究策略全面，整合了多组学数据库分析、单细胞测序解析、体内外功能验证以及中药活性成分筛选。核心发现是RNF130通过激活TNF-α通路促进肿瘤进展并介导免疫抑制微环境，而中药成分乌药碱可靶向抑制RNF130并与紫杉醇产生协同效应。创新性在于从单细胞层面揭示了RNF130的细胞特异性作用，并探索了传统药物成分的现代分子靶点，为TNBC的联合治疗提供了新思路。局限性在于，乌药碱与RNF130相互作用的直接分子证据以及更广泛的临床前药效学和毒性评估仍需进一步深入。

---

## 3. 局部转移性扩张与继发性器官内播散：由根本不同的转移定植模式解释的两种神经性死亡原因。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580751)
**期刊：** Molecular cancer
**PMID：** 41580751
**DOI：** 10.1186/s12943-026-02574-0

### 第一部分 原文与翻译

**英文原标题：** Local metastatic expansion versus secondary intra-organ dissemination: two causes of neurological death explained by fundamentally different metastatic colonization patterns.

> **英文摘要：**
> BACKGROUND: Neurological failure contributes to 15-50% of deaths in patients with brain metastases, yet the underlying mechanisms remain poorly understood. Clinical causes range from local compression to meningeal metastasis. In this context, a link between infiltrative histopathological growth patterns (HGPs) and meningeal metastasis was recently described and prompted this reverse translation study. METHODS: We conducted a retrospective postmortem histological assessment and a prospective MRI-based proof-of-concept study to explore neurological decline mechanisms in two experimental brain metastasis models with different HGPs: (i) the non-infiltrative TUBO model, characterized by well-defined tumor borders and a multilayered astrocytic capsule; and (ii) the infiltrative E0771-LG model, exhibiting diffuse infiltration and widespread astrogliosis. RESULTS: In the TUBO model, neurological death resulted from local metastatic expansion compressing vital structures, while the E0771-LG model caused mortality mainly through widespread secondary dissemination. We provide the first direct evidence of contralateral recolonization by secondary metastasis-initiating cells (secMICs), and highlight the high efficiency of secondary spread. Additionally, we show that secMICs exploit distinct anatomical structures to reach distant brain regions, bypassing classical vascular dissemination routes. Notably, the HGP and its associated features are intrinsic to tumor cells and are established early during metastatic colonization. CONCLUSIONS: This study identifies the HGP as a potential surrogate for predicting the underlying cause of organ failure in brain metastases. Additionally, it highlights the significant role of secondary dissemination and recolonization in brain metastasis, processes that have been largely overlooked in clinical practice. These findings address a critical knowledge gap and may inform future treatment strategies.

> **中文摘要：**
> 背景：神经功能衰竭导致15-50%的脑转移患者死亡，但其潜在机制仍知之甚少。临床原因从局部压迫到脑膜转移不等。在此背景下，最近描述了浸润性组织病理学生长模式（HGPs）与脑膜转移之间的联系，并促成了这项反向转化研究。方法：我们进行了一项回顾性尸检组织学评估和一项基于MRI的前瞻性概念验证研究，以探索两种具有不同HGPs的实验性脑转移模型中的神经功能衰退机制：（i）非浸润性TUBO模型，其特征是边界清晰的肿瘤和多层星形胶质细胞包膜；（ii）浸润性E0771-LG模型，表现为弥漫性浸润和广泛的星形胶质细胞增生。结果：在TUBO模型中，神经性死亡源于局部转移性扩张压迫关键结构，而E0771-LG模型主要通过广泛的继发性播散导致死亡。我们首次提供了继发性转移起始细胞（secMICs）对侧再定植的直接证据，并强调了继发性播散的高效性。此外，我们发现secMICs利用独特的解剖结构到达远处脑区，绕过了经典的血管播散途径。值得注意的是，HGP及其相关特征是肿瘤细胞固有的，并在转移定植早期就已确立。结论：本研究确定HGP可作为预测脑转移器官衰竭潜在原因的一个潜在替代指标。此外，它强调了继发性播散和再定植在脑转移中的重要作用，这些过程在临床实践中很大程度上被忽视了。这些发现填补了一个关键的知识空白，并可能为未来的治疗策略提供信息。

### 第二部分 AI 大师评价

本研究旨在通过反向转化策略，阐明不同组织病理学生长模式（HGP）如何决定脑转移患者神经功能衰竭的机制。研究者结合回顾性尸检与前瞻性MRI研究，在非浸润性与浸润性两种脑转移模型中揭示了导致死亡的两种根本不同模式：局部压迫性扩张与高效继发性播散。其核心创新在于首次直接证实了继发性转移起始细胞（secMICs）的对侧再定植现象及其利用非血管解剖结构播散的机制，将HGP确立为预测临床结局的早期内在决定因素。然而，研究主要基于实验模型，其结论向临床转化的普适性仍需在更广泛的患者队列和肿瘤类型中得到验证。

---

## 4. 前鞘脂激活蛋白通过协调施万细胞与胃癌细胞之间由TGFβ1驱动的旁分泌环路，加速胃癌的神经周围侵袭。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580724)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41580724
**DOI：** 10.1186/s13046-026-03652-3

### 第一部分 原文与翻译

**英文原标题：** Prosaposin orchestrates a TGFβ1-driven paracrine loop between Schwann cells and gastric cancer to accelerate perineural invasion.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索前鞘脂激活蛋白在胃癌神经周围侵袭中的作用机制。研究揭示了前鞘脂激活蛋白作为关键信号分子，在施万细胞与胃癌细胞之间建立了一个由TGFβ1驱动的旁分泌环路，从而促进了神经侵袭的进程。这一发现为理解肿瘤-神经微环境交互提供了新的分子机制，并可能为开发针对PNI的治疗策略提供潜在靶点。然而，由于摘要不可用，研究的具体实验设计、模型系统及关键数据细节尚不明确，其结论的普适性和转化潜力有待进一步验证。

---

## 5. 单个氨基酸差异定义了H2B变体，并通过改变染色质可及性诱导乳腺癌上皮-间质转化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580505)
**期刊：** Oncogene
**PMID：** 41580505
**DOI：** 10.1038/s41388-025-03636-1

### 第一部分 原文与翻译

**英文原标题：** Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer.

> **英文摘要：**
> Histones scaffold genomic DNA and regulate access to the transcriptional machinery. However, naturally occurring histone variants can alter histone-DNA interactions, DNA and histone modifications, and the chromatin interactome. Hence, alterations in histone variant deposition can disrupt chromatin, and are increasingly recognized as a way to trigger various disease, including cancer. While significant attention has been placed on the biochemical and functional roles of H2A, H3, and H4 histone variants, the variants of H2B remain largely understudied. Here, we show that H2B variants are dysregulated in breast cancer and that certain variants are associated with specific breast cancer subtypes. HIST1H2BO overexpression (in particular) is more common in Asian, African American/Black, and young female populations and is associated with a worse prognosis. In vitro studies show that H2B1O compacts nucleosome structure. Incorporating H2B1O into chromatin activates pro-inflammatory and oncogenic pathways, induces epithelial-to-mesenchymal transition (EMT), and generates resistance to first-line chemotherapeutic agents. Thus, H2B1O acts much like an onco-histone, with H2B variant expression being a prognostic biomarker for breast cancer and a potential new target for drug therapies to enhance treatment efficacy.

> **中文摘要：**
> 组蛋白为基因组DNA提供支架并调控转录机器的可及性。然而，天然存在的组蛋白变体可以改变组蛋白-DNA相互作用、DNA和组蛋白修饰以及染色质相互作用组。因此，组蛋白变体沉积的改变可以破坏染色质结构，并日益被认为是触发包括癌症在内的多种疾病的一种方式。尽管H2A、H3和H4组蛋白变体的生化和功能作用受到了广泛关注，但H2B的变体在很大程度上仍未得到充分研究。本文中，我们揭示了H2B变体在乳腺癌中失调，并且某些变体与特定的乳腺癌亚型相关。HIST1H2BO的过表达（尤其）在亚洲、非裔美国人/黑人和年轻女性人群中更为常见，并与较差的预后相关。体外研究表明，H2B1O致密了核小体结构。将H2B1O整合到染色质中会激活促炎和致癌通路，诱导上皮-间质转化（EMT），并产生对一线化疗药物的耐药性。因此，H2B1O的作用类似于癌组蛋白，H2B变体的表达可作为乳腺癌的预后生物标志物，并成为提高治疗疗效的潜在新药物靶点。

### 第二部分 AI 大师评价

本研究聚焦于乳腺癌中H2B组蛋白变体的功能，旨在阐明其通过改变染色质可及性驱动肿瘤进展的机制。研究通过分析临床数据关联和体外功能实验，发现HIST1H2BO/H2B1O在特定人群高表达且预后不良，并证实其能致密核小体、激活致癌通路、诱导EMT及化疗耐药。其创新性在于将长期被忽视的H2B变体确立为关键的“癌组蛋白”和潜在治疗靶点，为乳腺癌表观遗传调控提供了新视角。局限性在于研究主要基于体外模型和关联分析，其体内功能和具体分子机制有待进一步验证。

---

## 6. 靶向癌胚硫酸软骨素的抗体药物偶联物的临床前特征分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580438)
**期刊：** Cell death & disease
**PMID：** 41580438
**DOI：** 10.1038/s41419-026-08420-x

### 第一部分 原文与翻译

**英文原标题：** Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.

> **英文摘要：**
> Antibody-drug conjugates (ADC) offer a targeted cancer treatment approach by delivering cytotoxic payloads directly to tumor cells. However, resistance mechanisms, poor tumor penetration, and off-target toxicity often limit clinical efficacy. Vartumab targets oncofetal chondroitin sulfate (ofCS), a pan-cancer target present on tumor cells and in the malignant stroma, with low expression in normal tissues. As part of transitioning Vartumab to clinical evaluation, two linker-payloads known to mediate bystander effects, valine-citrulline (vc)-monomethyl auristatin E (MMAE) and glycine-glycine-phenylalanine-glycine (ggfg)-Deruxtecan (DXd), were investigated for design of Vartumab ADCs. We show that the ADCs maintain specificity to ofCS proteoglycans, cancer cells, and tissue biopsies, exhibiting specific binding to a wide range of malignant and metastatic tissues. Biodistribution assessment of Vartumab ADCs in mice shows strong and specific tumor uptake, with minimal accumulation in other organs. Both ADCs induced bystander killing of antigen-negative cells in the presence of antigen-positive cells and displayed potent anti-tumor activities in a cell-derived xenograft melanoma model. Furthermore, we show that Vartumab conjugates with bystander-capable linker-payloads exhibit greater in vivo potency compared to those with payloads lacking significant bystander effect. Finally, toxicity assessment in rats indicates that the ADC-MMAE is well-tolerated upon repeated doses, with similar dose-limiting toxicities as reported for clinically approved MMAE-conjugated ADCs. Our data support further clinical development of Vartumab-based ADCs.

> **中文摘要：**
> 抗体药物偶联物（ADC）通过将细胞毒性载荷直接递送至肿瘤细胞，提供了一种靶向癌症治疗方法。然而，耐药机制、肿瘤穿透性差以及脱靶毒性常常限制其临床疗效。Vartumab靶向癌胚硫酸软骨素（ofCS），这是一种存在于肿瘤细胞和恶性间质中的泛癌靶点，在正常组织中表达较低。作为将Vartumab推进至临床评估的一部分，我们研究了两种已知能介导旁观者效应的连接子-载荷——缬氨酸-瓜氨酸（vc）-单甲基奥瑞他汀E（MMAE）和甘氨酸-甘氨酸-苯丙氨酸-甘氨酸（ggfg）-Deruxtecan（DXd）——用于设计Vartumab ADC。我们证明，这些ADC保持了对ofCS蛋白聚糖、癌细胞和组织活检的特异性，能够与多种恶性和转移性组织特异性结合。在小鼠体内进行的Vartumab ADC生物分布评估显示，其在肿瘤中有强效且特异性的摄取，而在其他器官中积累极少。两种ADC在抗原阳性细胞存在的情况下，均能诱导对抗原阴性细胞的旁观者杀伤，并在细胞来源的异种移植黑色素瘤模型中显示出强大的抗肿瘤活性。此外，我们发现，与载荷缺乏显著旁观者效应的偶联物相比，采用具有旁观者效应能力的连接子-载荷的Vartumab偶联物在体内表现出更强的效力。最后，在大鼠中的毒性评估表明，ADC-MMAE在重复给药后耐受性良好，其剂量限制性毒性与已报道的临床获批的MMAE偶联ADC相似。我们的数据支持基于Vartumab的ADC的进一步临床开发。

### 第二部分 AI 大师评价

本研究旨在推进靶向癌胚硫酸软骨素（ofCS）的抗体Vartumab向临床转化，通过评估其与两种具有旁观者效应能力的连接子-载荷（vc-MMAE和ggfg-DXd）构建的ADC的临床前特征。核心发现包括：所构建的ADC保持了优异的靶向特异性与肿瘤富集能力，并能有效杀伤抗原阴性细胞，展现出强大的抗肿瘤活性；研究进一步证实，旁观者效应能力是提升ADC体内效力的关键因素，且初步毒性特征与已上市同类药物相似。其创新性在于聚焦于ofCS这一泛癌基质靶点，并系统比较了不同连接子-载荷策略的效能，为克服传统ADC的局限性提供了新思路。然而，研究仍处于临床前阶段，其人体内的安全性与疗效，以及针对不同癌种的适用性，尚待后续临床试验验证。

---

## 7. 调节Nudt21水平揭示选择性多聚腺苷酸化在组织再生中的剂量依赖性作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580420)
**期刊：** Nature communications
**PMID：** 41580420
**DOI：** 10.1038/s41467-026-68630-x

### 第一部分 原文与翻译

**英文原标题：** Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration.

> **英文摘要：**
> Stem cells continually self-renew and differentiate to sustain tissue homeostasis, yet the role of post-transcriptional mechanisms in guiding these processes remains incompletely understood. Here, we demonstrate that the regulation of 3'UTR length via alternative mRNA polyadenylation (APA) is essential for stem cell function across diverse tissues. Modulating the APA regulator Nudt21 reveals that stem cell self-renewal and differentiation depend on distinct dosage thresholds and thus can be uncoupled. Specifically, moderate Nudt21 suppression elicits a maturation arrest of stem cells due to 3'UTR-shortening of differentiation-associated mRNAs that escape miRNA regulation and perturb ceRNA networks. By contrast, complete Nudt21 suppression additionally shortens the 3'UTRs of mRNAs encoding essential multiprotein complexes, including the nuclear pore, leading to complex destabilization, proteotoxic stress, DNA damage, and cell cycle arrest. Critically, deletion of the alternative 3'UTRs of individual nucleoporins recapitulates defects observed with Nudt21 loss. We further demonstrate that the co-translational assembly of dozens of protein complexes is impaired in Nudt21-deficient cells, providing a mechanistic framework for compromised complex integrity. Collectively, our results show that APA plays distinct, dose-dependent roles in stem cell homeostasis by fine-tuning the expression of differentiation-associated genes and coordinating the biogenesis of multiprotein complexes essential for cell周期 progression.

> **中文摘要：**
> 干细胞通过持续的自我更新和分化来维持组织稳态，但转录后机制在指导这些过程中的作用仍未完全阐明。本文证明，通过选择性mRNA多聚腺苷酸化（APA）调控3'UTR长度对于多种组织中的干细胞功能至关重要。调节APA调控因子Nudt21揭示，干细胞的自我更新和分化依赖于不同的剂量阈值，因此可以解耦。具体而言，适度的Nudt21抑制会引发干细胞成熟停滞，这是由于分化相关mRNAs的3'UTR缩短，使其逃避miRNA调控并扰乱了ceRNA网络。相比之下，完全抑制Nudt21还会缩短编码必需多蛋白复合物（包括核孔复合物）的mRNAs的3'UTR，导致复合物不稳定、蛋白质毒性应激、DNA损伤和细胞周期停滞。关键的是，删除单个核孔蛋白的选择性3'UTR可以重现Nudt21缺失所观察到的缺陷。我们进一步证明，在Nudt21缺陷细胞中，数十种蛋白质复合物的共翻译组装受损，这为复合物完整性受损提供了机制性框架。总之，我们的结果表明，APA通过微调分化相关基因的表达以及协调细胞周期进展所必需的多蛋白复合物的生物合成，在干细胞稳态中发挥着不同的、剂量依赖性的作用。

### 第二部分 AI 大师评价

本研究旨在阐明选择性多聚腺苷酸化（APA）及其调控因子Nudt21在干细胞稳态和组织再生中的精确作用。通过剂量依赖性地调控Nudt21，研究揭示了APA对干细胞命运决定的精细调控机制：适度抑制影响分化相关基因网络，而完全抑制则破坏多蛋白复合物的生物合成。其创新性在于将APA的剂量效应与具体的分子机制（如ceRNA网络和共翻译组装）直接关联，为理解转录后调控在再生医学中的作用提供了新框架。局限性在于研究主要基于细胞和模型生物，其发现向人类生理病理及治疗应用的转化仍需进一步探索。

---

## 8. 基于点击化学反应测定分子在大肠杆菌中的积累

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580407)
**期刊：** Nature communications
**PMID：** 41580407
**DOI：** 10.1038/s41467-026-68717-5

### 第一部分 原文与翻译

**英文原标题：** Click-based determination of accumulation of molecules in Escherichia coli.

> **英文摘要：**
> Gram-negative bacterial pathogens pose a significant challenge in drug development because their outer membranes hinder the permeation of small molecules. The lack of widely adoptable methods for measuring the cytosolic accumulation of compounds in bacterial cells further hinders drug discovery efforts. To address this challenge, we report the development of the Chloroalkane Azide Membrane Permeability (CHAMP) assay, which we designed specifically to assess molecule accumulation in the cytosol of Gram-negative bacteria. The CHAMP analysis utilizes bioorthogonal epitopes anchored within HaloTag-expressing bacteria and measures the cytosolic arrival of azide-bearing test molecules through strain-promoted azide-alkyne cycloaddition. This workflow enables robust and rapid accumulation measurements of thousands of azide-tagged small molecules. Our approach consistently produces comprehensive accumulation profiles that surpass the scale of previous measurements in Escherichia coli (E. coli). We validated the CHAMP assay across various chemical and biological contexts, including hyperporinated cells, membrane-permeabilized cells, and E. coli strains with impaired TolC function, a key component of the efflux pump. The CHAMP platform provides a simple, high-throughput, and accessible method that enables the analysis of over 1000 molecules within hours. This technique addresses a critical gap in antimicrobial research and has the potential to accelerate the development of effective agents against Gram-negative pathogens.

> **中文摘要：**
> 革兰氏阴性细菌病原体因其外膜阻碍小分子渗透，给药物开发带来了重大挑战。缺乏广泛适用的方法来测量化合物在细菌细胞胞质内的积累，进一步阻碍了药物发现工作。为应对这一挑战，我们报告了氯烷叠氮化物膜通透性（CHAMP）检测方法的开发，该方法专为评估分子在革兰氏阴性细菌胞质内的积累而设计。CHAMP分析利用锚定在表达HaloTag的细菌内的生物正交表位，并通过应变促进的叠氮-炔环加成反应来测量携带叠氮基的测试分子到达胞质的情况。该工作流程能够对数千种叠氮标记的小分子进行稳健且快速的积累测量。我们的方法能持续生成全面的积累谱图，其规模超过了先前在大肠杆菌中的测量。我们在多种化学和生物学背景下验证了CHAMP检测，包括高孔化细胞、膜通透性改变的细胞以及外排泵关键组分TolC功能受损的大肠杆菌菌株。CHAMP平台提供了一种简单、高通量且易于使用的方法，能够在数小时内分析超过1000种分子。该技术解决了抗菌研究中的一个关键空白，并有望加速针对革兰氏阴性病原体的有效药物的开发。

### 第二部分 AI 大师评价

本研究旨在解决革兰氏阴性菌药物开发中，小分子胞内积累难以测量的核心瓶颈。研究者创新性地开发了CHAMP检测平台，该方法巧妙结合了HaloTag蛋白锚定技术与点击化学反应，实现了对数千种叠氮标记小分子在细菌胞质内积累的高通量、快速定量。其创新性在于首次提供了大规模、系统性的分子积累谱图，并在多种菌株模型中得到验证，为抗菌药物先导化合物的筛选与优化提供了强大工具。然而，该方法依赖于测试分子需预先标记叠氮基团，可能不适用于所有化合物库，且主要评估积累而非直接抗菌活性，后续仍需结合功能实验进行验证。

---

## 9. 缓殖子亚型主导弓形虫发育的十字路口。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580398)
**期刊：** Nature communications
**PMID：** 41580398
**DOI：** 10.1038/s41467-026-68489-y

### 第一部分 原文与翻译

**英文原标题：** Bradyzoite subtypes rule the crossroads of Toxoplasma development.

> **英文摘要：**
> Toxoplasmosis is a major risk to chronically infected individuals, especially those who become immunocompromised. Although one-third of the globe is infected with Toxoplasma, no treatments prevent or eliminate cysts in part due to limited understanding of bradyzoite biology. The cyst is central to Toxoplasmosis, as transition from bradyzoites to tachyzoites drive pathology. In this study, we aim to understand the biology of bradyzoites prior to recrudescence and the developmental pathways they initiate. Here, we discover ME49EW cysts from infected mice harbor multiple bradyzoite subtypes with distinct fates. Purified subtypes exhibit defined developmental pathways in animals and in primary astrocytes. Single-bradyzoite RNA-sequencing reveals five major subtypes within cysts. We further show that a crucial subtype in chronically infected mice is absent from a widely used in vitro model of bradyzoite development. Altogether, this work establishes new foundational principles of Toxoplasma cyst development and reactivation that operate during the intermediate life cycle of Toxoplasma.

> **中文摘要：**
> 弓形虫病对慢性感染个体，尤其是免疫功能低下者，构成重大风险。尽管全球有三分之一的人口感染弓形虫，但目前尚无治疗方法能够预防或清除包囊，部分原因在于对缓殖子生物学的理解有限。包囊是弓形虫病的核心，因为从缓殖子向速殖子的转化驱动了病理过程。在本研究中，我们旨在了解缓殖子在复发前的生物学特性及其启动的发育途径。我们发现，来自感染小鼠的ME49EW包囊含有多种具有不同命运的缓殖子亚型。纯化的亚型在动物和原代星形胶质细胞中表现出明确的发育途径。单缓殖子RNA测序揭示了包囊内的五种主要亚型。我们进一步证明，在慢性感染小鼠中的一个关键亚型，在一种广泛使用的缓殖子发育体外模型中并不存在。总而言之，这项工作确立了弓形虫包囊发育和再激活的新基本原理，这些原理在弓形虫的中间生命周期中发挥作用。

### 第二部分 AI 大师评价

本研究旨在深入探究弓形虫缓殖子在复发前的生物学特性及其发育路径。研究团队通过分析感染小鼠的包囊，结合单缓殖子RNA测序技术，创新性地发现了包囊内存在五种具有不同命运的缓殖子亚型，并明确了它们在体内外的特定发育路径。其核心发现在于，鉴定出一种在慢性感染小鼠中至关重要、却在常用体外模型中缺失的缓殖子亚型，这揭示了现有体外模型的局限性。该工作为理解弓形虫包囊的异质性、发育调控及再激活机制奠定了新的理论基础，对开发靶向包囊的治疗策略具有重要启示。

---

## 10. 回复Harry Herr致编辑的信：关于Oscar Buisan、Pol Servian、Sonia Pedreño-Lopez等人的《一种利用RUTI疫苗的新型异源初免-加强策略以改善非肌层浸润性膀胱癌患者对卡介苗的反应：RUTIVAC-1 I期试验》。Eur Urol。印刷中。https://doi.org/10.1016/j.eururo.2025.08.014。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580335)
**期刊：** European urology
**PMID：** 41580335
**DOI：** 10.1016/j.eururo.2026.01.012

### 第一部分 原文与翻译

**英文原标题：** Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.014.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对读者来信的回复，核心内容围绕一项旨在改善非肌层浸润性膀胱癌（NMIBC）患者卡介苗（BCG）治疗反应的I期临床试验（RUTIVAC-1）展开。该试验的创新性在于探索了一种异源初免-加强策略，即使用RUTI疫苗来增强BCG的免疫应答。由于原文为信件回复且无摘要，其具体方法细节、初步发现及安全性数据需参考原始研究论文。这种策略为克服BCG治疗反应不足或复发的临床挑战提供了新的免疫治疗思路，但其有效性与安全性尚需后续更大规模的临床试验验证。

---

## 11. 纳武利尤单抗辅助治疗用于已切除的高危头颈癌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580292)
**期刊：** Lancet (London, England)
**PMID：** 41580292
**DOI：** 10.1016/S0140-6736(26)00133-9

### 第一部分 原文与翻译

**英文原标题：** Adjuvant nivolumab for resected high-risk head and neck cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在评估免疫检查点抑制剂纳武利尤单抗作为辅助治疗，用于已接受手术切除的高危头颈癌患者的疗效与安全性。其核心方法是在根治性手术后，通过免疫治疗干预以清除微小残留病灶，从而降低复发风险、改善患者长期生存。该研究有望为高危头颈癌患者提供新的术后标准治疗选择，其创新性在于将免疫治疗前移至辅助治疗阶段。然而，由于摘要信息缺失，其具体研究设计（如随机对照试验或单臂研究）、主要终点结果、安全性数据以及与传统辅助治疗（如放疗或化疗）的比较优势等关键细节尚不明确，需查阅全文以全面评估其临床价值与局限性。

---

## 12. 量化体力活动对公共卫生的影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580291)
**期刊：** Lancet (London, England)
**PMID：** 41580291
**DOI：** 10.1016/S0140-6736(26)00093-0

### 第一部分 原文与翻译

**英文原标题：** Quantifying the public health impact of physical activity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在通过量化评估方法，系统阐述体力活动对公共卫生的总体影响。其核心目的可能是建立体力活动与人群健康结局之间的量化关联模型，为公共卫生决策提供循证依据。鉴于摘要不可用，推测其方法可能涉及系统综述、荟萃分析或疾病负担研究。其创新性在于将体力活动的健康效益进行整体性、定量化的评估，但缺乏具体摘要信息限制了对其研究方法、关键发现及潜在局限性的深入理解。

---

## 13. 孕烯醇酮通过阻断内源性逆转录病毒表达促进免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41579859)
**期刊：** Cell metabolism
**PMID：** 41579859
**DOI：** 10.1016/j.cmet.2025.12.020

### 第一部分 原文与翻译

**英文原标题：** Pregnenolone promotes immune evasion through blocking endogenous retrovirus expression.

> **英文摘要：**
> Research into steroid hormones shaping tumor biology has gained increasing attention. Using multiple mouse tumor models, we show that pregnenolone promoted tumor progression and reduced sensitivity to immunotherapy. Pregnenolone levels were markedly elevated in maternal mice experiencing mating deficiency. Mechanistically, pregnenolone directly binds Kap1 and inhibits Trim39-mediated ubiquitination at K750, leading to Kap1 stabilization and repression of endogenous retrovirus (ERV) expression and type-I interferon production. Furthermore, pharmacological antagonism of pregnenolone effectively suppressed tumor growth and enhanced immunotherapy efficacy. These findings reveal a previously unrecognized link between mating-associated steroid metabolism and tumor immune regulation and identify pregnenolone signaling as a potential therapeutic target in cancer.

> **中文摘要：**
> 关于类固醇激素塑造肿瘤生物学的研究日益受到关注。利用多种小鼠肿瘤模型，我们发现孕烯醇酮能促进肿瘤进展并降低对免疫治疗的敏感性。在经历交配缺陷的母鼠中，孕烯醇酮水平显著升高。从机制上讲，孕烯醇酮直接结合Kap1并抑制Trim39介导的K750位点泛素化，从而导致Kap1稳定化，并抑制内源性逆转录病毒（ERV）表达和I型干扰素的产生。此外，孕烯醇酮的药理学拮抗作用有效抑制了肿瘤生长并增强了免疫治疗疗效。这些发现揭示了交配相关的类固醇代谢与肿瘤免疫调节之间先前未被认识到的联系，并将孕烯醇酮信号通路确定为癌症的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探索类固醇激素孕烯醇酮在肿瘤免疫逃逸中的作用。研究者采用多种小鼠肿瘤模型，结合分子机制探索，发现孕烯醇酮通过稳定Kap1蛋白抑制内源性逆转录病毒表达和I型干扰素产生，从而削弱免疫治疗效果。其创新性在于首次将交配行为相关的激素代谢变化与肿瘤免疫调控联系起来，并提出了靶向孕烯醇酮信号的治疗策略。局限性在于主要发现基于小鼠模型，其在人类肿瘤中的普适性及临床转化潜力仍需进一步验证。

---

## 14. NuMA通过稳定连接组蛋白H1在染色质上的结合来促进组成型异染色质的压缩。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41579374)
**期刊：** Cell reports
**PMID：** 41579374
**DOI：** 10.1016/j.celrep.2025.116901

### 第一部分 原文与翻译

**英文原标题：** NuMA promotes constitutive heterochromatin compaction by stabilizing linker histone H1 on chromatin.

> **英文摘要：**
> Heterochromatin exerts pivotal functions of silencing specific genes and maintenance of genome stability. However, its formation and maintenance mechanisms remain unclear. Here, we discover that the mitotic regulator NuMA, as a nucleoskeleton protein, is required for constitutive heterochromatin organization at the nucleosome level in interphase. NuMA depletion results in shortened nucleosome repeat length, dispersed nucleosome clutches, increased chromatin accessibility, and disrupted transcription repression of long terminal repeats in heterochromatin regions. Such functions of NuMA rely on its interaction with linker histone H1, which stabilizes H1's binding to chromatin and facilitates nucleosome stacking, as directly visualized by in situ cryo-ET. Notably, NuMA oligomerizes into quasi-meshwork in the nucleoplasm, providing its organization basis as a nucleoskeleton protein. Collectively, our findings illuminate the concerted effect of nucleoskeleton and linker histone on chromatin compaction at the nucleosome level, unveiling a previously unexplored mechanism by which nucleoskeleton regulates heterochromatin formation and maintenance.

> **中文摘要：**
> 异染色质在沉默特定基因和维持基因组稳定性方面发挥着关键作用。然而，其形成和维持机制仍不清楚。本研究揭示，有丝分裂调节因子NuMA作为一种核骨架蛋白，是间期核小体水平上组成型异染色质结构所必需的。NuMA的缺失导致核小体重复长度缩短、核小体簇分散、染色质可及性增加，并破坏了异染色质区域长末端重复序列的转录抑制。NuMA的这些功能依赖于其与连接组蛋白H1的相互作用，该作用稳定了H1与染色质的结合并促进核小体堆叠，这一点通过原位冷冻电子断层扫描技术得以直接观察。值得注意的是，NuMA在核质中寡聚形成类网状结构，这为其作为核骨架蛋白的组织功能提供了基础。总之，我们的研究结果阐明了核骨架和连接组蛋白在核小体水平上对染色质压缩的协同作用，揭示了一种先前未被探索的、核骨架调控异染色质形成与维持的机制。

### 第二部分 AI 大师评价

本研究旨在阐明核骨架蛋白NuMA在组成型异染色质结构维持中的新功能。通过结合分子生物学、成像（原位冷冻电镜）和功能缺失实验，发现NuMA通过稳定连接组蛋白H1在染色质上的结合，促进核小体堆叠与染色质压缩，从而调控异染色质的结构和基因沉默功能。其创新性在于首次揭示了NuMA作为核骨架组分在间期染色质高级结构组织中的直接作用，并提出了核骨架与连接组蛋白协同调控异染色质的新机制。局限性在于，研究主要基于体外和细胞模型，其在复杂生物体生理及病理条件下的具体调控网络和功能仍有待进一步探索。

---

## 15. 气道损伤诱导巨噬细胞介导的肺泡上皮反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41579370)
**期刊：** Cell reports
**PMID：** 41579370
**DOI：** 10.1016/j.celrep.2025.116881

### 第一部分 原文与翻译

**英文原标题：** Airway injury induces alveolar epithelial responses mediated by macrophages.

> **英文摘要：**
> Airway injury activates local progenitors and stimulates cell-cell interactions to restore homeostasis, but it is unknown how distal niches are impacted. We utilized mouse models of airway-specific epithelial injury to examine secondary tissue-wide alveolar and immune responses. Single-cell transcriptomics and in vivo validation of mouse models of airway-specific epithelial injury revealed transient, tissue-wide proliferation of alveolar type 2 (AT2) progenitor cells after club cell-specific injury or ablation. Myeloid cells exhibited altered gene expression after club cell loss and were detectable in the bronchoalveolar lavage fluid. The AT2 cell proliferative response was reliant on alveolar macrophages (AMs) exhibiting an injury-induced gene expression program. Overall, these results demonstrate that acute airway damage can trigger myeloid-mediated lung alveolar responses that may contribute to disease susceptibility or dysfunction.

> **中文摘要：**
> 气道损伤会激活局部祖细胞并刺激细胞间相互作用以恢复稳态，但尚不清楚远端生态位如何受到影响。我们利用气道特异性上皮损伤的小鼠模型来研究继发的组织范围肺泡和免疫反应。通过单细胞转录组学和对气道特异性上皮损伤小鼠模型的体内验证，发现棒状细胞特异性损伤或消融后，肺泡2型祖细胞会发生短暂的组织范围增殖。棒状细胞缺失后，髓系细胞表现出基因表达改变，并可在支气管肺泡灌洗液中检测到。AT2细胞的增殖反应依赖于表现出损伤诱导基因表达程序的肺泡巨噬细胞。总之，这些结果表明，急性气道损伤可触发髓系细胞介导的肺泡反应，这可能与疾病易感性或功能障碍有关。

### 第二部分 AI 大师评价

本研究旨在探究气道局部损伤如何影响远端肺泡生态位，揭示了肺部不同区域间的细胞通讯机制。研究者通过构建气道特异性损伤的小鼠模型，结合单细胞转录组学和体内验证，系统分析了继发性组织反应。核心发现是，棒状细胞损伤可诱导肺泡巨噬细胞发生基因程序改变，进而介导远端AT2祖细胞的短暂增殖。该研究创新性地阐明了“气道-肺泡”轴中巨噬细胞的关键介导作用，为理解肺部损伤修复和疾病易感性提供了新视角；局限性在于主要基于小鼠模型，其结论在人类中的普适性及具体的分子信号通路有待进一步验证。

---

## 16. 鼻咽部EB病毒阳性神经内分泌癌的全外显子组测序分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41579269)
**期刊：** Endocrine pathology
**PMID：** 41579269
**DOI：** 10.1007/s12022-026-09902-6

### 第一部分 原文与翻译

**英文原标题：** Whole-Exome Profiling of Epstein-Barr Virus-Positive Neuroendocrine Carcinoma of the Nasopharynx.

> **英文摘要：**
> Epstein-Barr virus (EBV)-positive neuroendocrine carcinoma (NEC) of the nasopharynx is a rare malignancy with poor prognosis and lacks squamous markers, rendering it biologically distinct from nasopharyngeal carcinoma (NPC) of squamous epithelial origin. However, its molecular features remain largely undefined, and the entity has not been formally recognized as a nasopharyngeal carcinoma subtype, substantially limiting advances in its diagnosis and treatment. In this study, we performed whole-exome sequencing on seven EBV-positive nasopharyngeal NECs. These tumors exhibited a high tumor mutational burden and recurrent mutations in TP53, APC, and PROK2, with enrichment of alterations in the TP53/WNT, NOTCH, and RTK/RAS/PI3K pathways-mimicking the genomic landscape of NECs at other anatomical sites but clearly diverging from that of NPC. In addition, we identified potentially actionable alterations involving TP53 and KMT2A, suggesting avenues for targeted therapeutic exploration. Collectively, our findings provide molecular evidence supporting EBV-positive NEC of the nasopharynx as a distinct clinicopathologic entity, and offer valuable insights into its oncogenesis and potential therapeutic vulnerabilities.

> **中文摘要：**
> 鼻咽部EB病毒（EBV）阳性神经内分泌癌（NEC）是一种预后不良的罕见恶性肿瘤，且缺乏鳞状标志物，这使其在生物学上不同于鳞状上皮来源的鼻咽癌（NPC）。然而，其分子特征在很大程度上仍未明确，且该实体尚未被正式认定为鼻咽癌的一个亚型，这极大地限制了其诊断和治疗的进展。在本研究中，我们对七例EBV阳性鼻咽NEC进行了全外显子组测序。这些肿瘤表现出高肿瘤突变负荷以及TP53、APC和PROK2基因的反复突变，并富集了TP53/WNT、NOTCH和RTK/RAS/PI3K通路的改变——这模拟了其他解剖部位NEC的基因组图谱，但与NPC的图谱明显不同。此外，我们发现了涉及TP53和KMT2A的潜在可干预性改变，为靶向治疗探索提供了途径。总之，我们的研究结果为支持鼻咽部EBV阳性NEC作为一个独特的临床病理实体提供了分子证据，并为其肿瘤发生机制和潜在的治疗弱点提供了有价值的见解。

### 第二部分 AI 大师评价

本研究旨在通过全外显子组测序，阐明罕见且预后不良的鼻咽部EBV阳性神经内分泌癌（NEC）的分子特征。通过对7例肿瘤样本的分析，研究发现其具有高肿瘤突变负荷及TP53、APC等基因的特定突变模式，其基因组图谱与鳞状上皮来源的鼻咽癌（NPC）截然不同，却与其他部位的NEC相似，这为将其确立为独立的临床病理实体提供了关键的分子证据。研究的创新性在于首次系统描绘了该罕见肿瘤的分子图谱，并识别出TP53、KMT2A等潜在治疗靶点，为精准治疗提供了方向；主要局限性在于样本量较小，需要在更大规模的队列中进行验证。

---

## 17. GREM1从旁分泌到自分泌的转换通过ACVR1C驱动结直肠癌转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41578299)
**期刊：** Molecular cancer
**PMID：** 41578299
**DOI：** 10.1186/s12943-025-02554-w

### 第一部分 原文与翻译

**英文原标题：** A paracrine-to-autocrine shunt of GREM1 fuels colorectal cancer metastasis via ACVR1C.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究聚焦于结直肠癌转移机制，核心在于揭示了GREM1信号从肿瘤微环境中的旁分泌模式向肿瘤细胞自身自分泌模式的转换（即“分流”），并阐明其通过激活ACVR1C受体来驱动转移。这一发现为理解肿瘤细胞如何劫持并内化微环境信号以促进恶性进展提供了新视角，具有重要的机制创新性。然而，摘要缺失限制了对其具体实验方法、关键数据及潜在局限性的初步评估。

---

## 18. 胶原结合粘附素限制金黄色葡萄球菌皮肤感染。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41578135)
**期刊：** Nature communications
**PMID：** 41578135
**DOI：** 10.1038/s41467-026-68788-4

### 第一部分 原文与翻译

**英文原标题：** Collagen binding adhesin restricts Staphylococcus aureus skin infection.

> **英文摘要：**
> Staphylococcus aureus causes approximately 80% of skin and soft tissue infections (SSTIs). Collagen is the most abundant human extracellular matrix protein with critical roles in wound healing, and S. aureus encodes a collagen binding adhesin (Cna). The role of this protein during skin infections is unknown. Here we report that inability to bind collagen results in worsened pathology of intradermal Δcna S. aureus infection. WT/Cna+ S. aureus shows reduced infection severity, aggregate formation, and significantly improves clearance of bacteria. Cna binds to the collagen-like domain of serum C1q protein to reduce its opsonophagocytic functions. We demonstrate that infection of C1qKO mice with WT bacteria show results similar to the Δcna group. Conversely, inability to bind collagen results in an amplified inflammatory response caused in part by macrophage and neutrophil small molecule mediators released at the infection site (MMP-9, MMP-12, LTB), leading to increased immune cell infiltration and death.

> **中文摘要：**
> 金黄色葡萄球菌导致了大约80%的皮肤和软组织感染。胶原蛋白是人类最丰富的细胞外基质蛋白，在伤口愈合中起着关键作用，而金黄色葡萄球菌编码一种胶原结合粘附素。该蛋白在皮肤感染中的作用尚不清楚。本文报告，无法结合胶原蛋白会导致皮内Δcna金黄色葡萄球菌感染的病理恶化。野生型/Cna+金黄色葡萄球菌表现出感染严重程度降低、聚集体形成减少，并显著改善了细菌的清除。Cna与血清C1q蛋白的胶原样结构域结合，从而降低其调理吞噬功能。我们证明，用野生型细菌感染C1qKO小鼠，其结果与Δcna组相似。相反，无法结合胶原蛋白会导致放大的炎症反应，这部分是由感染部位释放的巨噬细胞和中性粒细胞小分子介质（MMP-9、MMP-12、LTB）引起的，从而导致免疫细胞浸润和死亡增加。

### 第二部分 AI 大师评价

本研究旨在阐明金黄色葡萄球菌胶原结合粘附素在皮肤感染中的具体功能。通过构建基因敲除菌株和动物模型，结合分子机制探究，发现Cna通过结合血清C1q的胶原样结构域抑制其调理吞噬功能，从而意外地减轻了感染病理，这一发现颠覆了粘附素通常促进感染的认知。研究创新性地揭示了细菌粘附素可通过“劫持”宿主补体成分来调节免疫反应的新机制，但结论主要基于小鼠模型，其在人体感染中的普适性及具体信号通路有待进一步验证。

---

## 19. CAR-T细胞疗法在儿童、青少年和年轻成人癌症患者中的核心作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41578095)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41578095
**DOI：** 10.1038/s41571-025-01115-w

### 第一部分 原文与翻译

**英文原标题：** The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

> **英文摘要：**
> Early successes achieved with the CD19-targeted chimeric antigen receptor (CAR) T cell product tisagenlecleucel for the treatment of paediatric B cell acute lymphoblastic leukaemia (B-ALL) led to a historic first FDA approval of a gene therapy. Widespread CAR T cell commercialization followed, along with expansion to other indications and earlier disease settings owing to clear survival benefits. However, commercial development of additional cell therapies for paediatric malignancies has stagnated, despite several products being brought to market as treatments for various haematological malignancies in adults. In contrast to the consistent efficacy achieved across B cell malignancies, CAR T cell approaches have yet to demonstrate durable activity in patients with acute myeloid leukaemia (AML), T cell acute lymphoblastic leukaemia, solid tumours and/or central nervous system cancers, with both biological factors and broader issues of development and access constraining the field. Herein, we showcase the foundational leaps achieved through the initial trials and commercialization of CAR T cell products and contextualize how these early experiences have moulded the field. We review currently approved and investigational CAR T cell therapies for paediatric and young-adult patients, including key considerations regarding safety, access and future directions. We also discuss additional immunotherapy options that guide clinical decision-making regarding optimal utilization of CAR T cells. Although clearly tolerable and efficacious, the CD19-targeted CAR T cell strategy requires ongoing refinement, and research efforts are now geared towards fully exploiting CAR T cells and other immunotherapies to improve survival with broadened access across disease states.

> **中文摘要：**
> 靶向CD19的嵌合抗原受体（CAR）T细胞产品tisagenlecleucel在治疗儿童B细胞急性淋巴细胞白血病（B-ALL）方面取得的早期成功，促成了基因疗法获得FDA历史性的首次批准。随后，CAR-T细胞疗法实现了广泛的商业化，并因其明确的生存获益而扩展到其他适应症和更早期的疾病阶段。然而，尽管已有数款产品作为成人多种血液恶性肿瘤的治疗方法上市，针对儿童恶性肿瘤的其他细胞疗法的商业开发却停滞不前。与在B细胞恶性肿瘤中取得的一致疗效相比，CAR-T细胞方法尚未在急性髓系白血病（AML）、T细胞急性淋巴细胞白血病、实体瘤和/或中枢神经系统癌症患者中展现出持久的活性，这既受生物学因素限制，也受开发和可及性等更广泛问题的制约。在此，我们展示了通过CAR-T细胞产品的初步试验和商业化所实现的基础性飞跃，并阐述了这些早期经验如何塑造了该领域。我们回顾了目前针对儿童和年轻成人患者已获批和正在研究中的CAR-T细胞疗法，包括关于安全性、可及性和未来方向的关键考量。我们还讨论了指导临床决策以优化CAR-T细胞使用的其他免疫治疗方案。尽管靶向CD19的CAR-T细胞策略显然具有耐受性和有效性，但仍需持续改进，目前的研究工作正致力于充分利用CAR-T细胞和其他免疫疗法，以改善生存率，并扩大其在各种疾病状态中的可及性。

### 第二部分 AI 大师评价

本文是一篇综述，旨在系统阐述CAR-T细胞疗法在儿童、青少年及年轻成人癌症患者中的应用现状与挑战。文章通过回顾CD19靶向CAR-T在B-ALL中的成功历史及其商业化进程，肯定了该疗法的基石地位。同时，作者客观指出了当前CAR-T疗法在AML、T-ALL及实体瘤等领域疗效有限、发展不均的局限性，并强调了生物学障碍及可及性问题。其创新性在于将历史经验、现状分析与未来方向（如联合其他免疫疗法、扩大可及性）相结合，为优化该人群的临床决策提供了全面的视角框架。

---

## 20. 可溶性E-钙黏蛋白-CXCL1-CXCR2轴：炎性乳腺癌脑转移中的一个治疗脆弱性靶点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41578012)
**期刊：** Neuro-oncology
**PMID：** 41578012
**DOI：** 10.1093/neuonc/noag012

### 第一部分 原文与翻译

**英文原标题：** Soluble E-cadherin-CXCL1-CXCR2 Axis as a Therapeutic Vulnerability in Inflammatory Breast Cancer Brain Metastasis.

> **英文摘要：**
> BACKGROUND: The brain is a common site of relapse in inflammatory breast cancer (IBC), an E-cadherin-positive, aggressive form of breast cancer. Elevated serum levels of soluble E-cadherin (sEcad), an 80-kDa fragment, correlated with poorer outcomes and increased brain metastases in patients with metastatic IBC. We hypothesize that sEcad is a driver of brain metastasis in IBC. METHODS: Serum sEcad levels from 348 IBC patients were quantified by ELISA. To examine sEcad function, we used recombinant sEcad protein and generated stable IBC cell lines by cloning and overexpressing Flag-tagged sEcad. Control and sEcad-overexpressing MDA-IBC3 and SUM149 cells were injected into SCID/Beige mice to evaluate brain metastasis burden and survival, and a brain-permeable CXCR2 inhibitor was also tested for efficacy in these models. RESULTS: Higher serum sEcad levels correlated with poorer overall survival, earlier metastasis, and increased brain metastasis. In vitro, recombinant sEcad and stable sEcad overexpression in IBC cell lines promoted invasion, resistance to anoikis, and activation of pro-survival NF-κβ signaling. In vivo, mice injected with sEcad-overexpressing IBC cells had increased metastatic burden and reduced overall and brain metastasis-free survival. Further, sEcad induced reactive astrocytosis through the CXCL1/CXCL8-CXCR2 axis, and treatment with a brain-permeable CXCR2 antagonist reduced metastatic burden and prolonged survival in the brain metastasis models. CONCLUSION: sEcad drives brain metastasis by promoting invasion and anoikis resistance in cancer cells and inducing an inflammatory brain microenvironment via a targetable CXCL1/CXCL8-CXCR2 axis. These findings uncover a novel and critical role for sEcad and highlight CXCR2 as a therapeutic target in patients with metastatic IBC.

> **中文摘要：**
> 背景：大脑是炎性乳腺癌（IBC）常见的复发部位，IBC是一种E-钙黏蛋白阳性的侵袭性乳腺癌。可溶性E-钙黏蛋白（sEcad）是一种80-kDa的片段，其血清水平升高与转移性IBC患者较差的预后和增加的脑转移相关。我们假设sEcad是IBC脑转移的驱动因素。方法：通过ELISA定量检测了348名IBC患者的血清sEcad水平。为了研究sEcad的功能，我们使用了重组sEcad蛋白，并通过克隆和过表达Flag标签标记的sEcad构建了稳定的IBC细胞系。将对照和过表达sEcad的MDA-IBC3及SUM149细胞注射到SCID/Beige小鼠体内，以评估脑转移负荷和生存情况，并在此模型中测试了一种脑渗透性CXCR2抑制剂的疗效。结果：较高的血清sEcad水平与较差的总体生存期、较早的转移发生以及增加的脑转移相关。在体外，重组sEcad和在IBC细胞系中稳定过表达sEcad促进了侵袭、失巢凋亡抵抗以及促生存NF-κβ信号通路的激活。在体内，注射了过表达sEcad的IBC细胞的小鼠转移负荷增加，总体生存期和脑转移无复发生存期缩短。此外，sEcad通过CXCL1/CXCL8-CXCR2轴诱导反应性星形胶质细胞增生，而使用脑渗透性CXCR2拮抗剂治疗可减少脑转移模型中的转移负荷并延长生存期。结论：sEcad通过促进癌细胞的侵袭和失巢凋亡抵抗，并通过可靶向的CXCL1/CXCL8-CXCR2轴诱导炎症性脑微环境，从而驱动脑转移。这些发现揭示了sEcad的一个新的关键作用，并强调了CXCR2作为转移性IBC患者的一个治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探究炎性乳腺癌脑转移的新机制和治疗靶点。研究者通过临床队列分析、体外细胞功能实验和体内动物模型，系统性地验证了可溶性E-钙黏蛋白（sEcad）作为驱动因子的作用，并揭示了其通过CXCL1/CXCL8-CXCR2轴诱导脑微环境炎症的机制。核心发现是sEcad-CXCL1-CXCR2轴是IBC脑转移的关键通路，且靶向CXCR2在动物模型中显示出治疗潜力。其创新性在于将sEcad这一生物学标志物与肿瘤微环境中的炎症轴联系起来，为转移性IBC提供了新的治疗思路。局限性在于研究主要基于临床前模型，其结论向临床转化的有效性仍需后续临床试验验证。

---

## 21. 基于慢性髓系白血病干血斑的下一代测序：对全球肿瘤学的启示与意义

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577999)
**期刊：** Leukemia
**PMID：** 41577999
**DOI：** 10.1038/s41375-025-02852-8

### 第一部分 原文与翻译

**英文原标题：** Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.

> **英文摘要：**
> The goal of the "Spot On CML" program is to provide diagnostic and monitoring tests to chronic myeloid leukemia (CML) patients in low- and middle-income countries (LMICs). Previously, we demonstrated reproducible BCR::ABL1 transcript quantification using dried blood spots (DBS). We have now optimized methods of DNA and RNA extraction from DBS, allowing the detection of myeloid gene variants, including ABL1 tyrosine kinase domain mutations. Among 177 CML patients from nine countries, ABL1 mutations were identified in 61 (34%) patients, with multiple mutations present in some cases. The most common ABL1 mutation was T315I (45.9% of patients with ABL1 mutations). Among 69 patients, 89 Tier I-II variants (pathogenic or likely pathogenic) were identified in other genes, including 52 ASXL1 variants in 49 patients. The detection of ASXL1 variants correlated strongly with the presence of ABL1 mutations (P = 3.51E-04). These methodologies are directly applicable to all assays used for the diagnosis, prognosis, and monitoring of CML and have important implications in bringing state-of-the-art genetic analysis to CML patients in LMICs.

> **中文摘要：**
> "Spot On CML"项目旨在为中低收入国家（LMICs）的慢性髓系白血病（CML）患者提供诊断和监测检测。此前，我们已证明使用干血斑（DBS）可重复定量BCR::ABL1转录本。目前，我们优化了从DBS中提取DNA和RNA的方法，从而能够检测髓系基因变异，包括ABL1酪氨酸激酶结构域突变。在来自九个国家的177名CML患者中，61名（34%）患者检测到ABL1突变，部分病例存在多重突变。最常见的ABL1突变是T315I（占ABL1突变患者的45.9%）。在69名患者中，在其他基因中鉴定出89个I-II级变异（致病性或可能致病性），包括在49名患者中发现的52个ASXL1变异。ASXL1变异的检测与ABL1突变的存在密切相关（P=3.51E-04）。这些方法可直接应用于所有用于CML诊断、预后和监测的检测，对于将先进的遗传分析技术带给LMICs的CML患者具有重要意义。

### 第二部分 AI 大师评价

本研究旨在通过优化干血斑（DBS）的核酸提取与测序技术，为资源有限地区提供CML的精准诊断与监测方案。其核心创新在于将DBS样本成功应用于NGS检测，不仅验证了BCR::ABL1定量，还拓展至ABL1激酶区突变及其他髓系相关基因（如ASXL1）变异的发现。研究发现ABL1突变率较高（34%），且ASXL1变异与ABL1突变显著相关，这为CML的疾病机制与耐药研究提供了新线索。然而，研究样本主要来自特定项目，需进一步扩大样本以验证其普适性，且DBS在低病毒载量或复杂变异检测中的性能仍需评估。

---

## 22. 人类共翻译N-豆蔻酰化的结构基础

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577716)
**期刊：** Nature communications
**PMID：** 41577716
**DOI：** 10.1038/s41467-025-67962-4

### 第一部分 原文与翻译

**英文原标题：** Structural basis of co-translational N-myristoylation in humans.

> **英文摘要：**
> Modifications of proteins occurring during translation are critical for protein localization, stability and function. N-myristoylation is an essential N-terminal lipid modification catalyzed co-translationally by N-myristoyltransferases (NMTs) which have been identified as promising drug targets. However, its molecular basis in the context of the translating ribosome is not known. Here, we reveal the structural basis for co-translational N-myristoylation by NMT1 on the human ribosome by cryo-electron microscopy (cryo-EM). We show that NMT1 binds near the peptide tunnel exit and interacts with the nascent polypeptide-associated complex (NAC). Unlike other multi-enzyme complexes that act simultaneously, we find that methionine excision by methionine aminopeptidases and N-myristoylation occur sequentially via consecutive binding to the ribosome. Furthermore, our data suggest that NMT1 remains associated with elongating nascent chains, indicating a co-translational chaperone-like function in partnership with NAC. These insights provide a molecular foundation for the understanding of the co-translational N-myristoylation mechanism in humans.

> **中文摘要：**
> 翻译过程中发生的蛋白质修饰对于蛋白质的定位、稳定性和功能至关重要。N-豆蔻酰化是一种由N-豆蔻酰转移酶（NMTs）共翻译催化的必需N端脂质修饰，NMTs已被确定为有前景的药物靶点。然而，其在翻译核糖体背景下的分子基础尚不清楚。在此，我们通过冷冻电子显微镜（cryo-EM）揭示了NMT1在人类核糖体上进行共翻译N-豆蔻酰化的结构基础。我们发现NMT1结合在肽通道出口附近，并与新生多肽相关复合物（NAC）相互作用。与其他同时作用的多酶复合物不同，我们发现甲硫氨酸氨基肽酶介导的甲硫氨酸切除和N-豆蔻酰化是通过依次结合核糖体而顺序发生的。此外，我们的数据表明NMT1与正在延伸的新生链保持结合，这表明其与NAC协同具有一种共翻译的分子伴侣样功能。这些发现为理解人类共翻译N-豆蔻酰化机制提供了分子基础。

### 第二部分 AI 大师评价

本研究旨在阐明人类细胞中N-豆蔻酰转移酶NMT1在核糖体上进行共翻译N-豆蔻酰化的分子机制。研究团队采用冷冻电镜技术，成功解析了NMT1与人类核糖体及NAC复合物结合的结构，揭示了其结合位点与相互作用模式。核心发现包括：首次在结构上展示了NMT1在核糖体上的工作场景；明确了甲硫氨酸切除与N-豆蔻酰化是顺序发生的两个独立步骤，而非同时进行；并提出了NMT1可能通过与NAC合作，在翻译延伸过程中发挥类似分子伴侣的功能。该研究的创新性在于首次在人类系统中以高分辨率揭示了这一关键翻译后修饰的共翻译结构基础，为靶向NMT的药物设计提供了精确模板。局限性在于，研究主要基于静态结构，动态的酶促反应过程及在更复杂细胞环境中的调控机制仍需进一步探索。

---

## 23. 作者更正：SOX2通过重编程脂质代谢和组蛋白乙酰化景观驱动食管鳞状细胞癌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577714)
**期刊：** Nature communications
**PMID：** 41577714
**DOI：** 10.1038/s41467-026-68461-w

### 第一部分 原文与翻译

**英文原标题：** Author Correction: SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在阐明转录因子SOX2在食管鳞状细胞癌（ESCC）中的致癌机制。研究聚焦于SOX2如何通过重编程肿瘤细胞的脂质代谢和改变组蛋白乙酰化修饰来驱动肿瘤发生。其创新性在于将代谢重编程与表观遗传调控联系起来，揭示了SOX2作为关键驱动因子的新功能。然而，作为一篇作者更正，其核心发现已在原文章中阐述，且当前信息缺乏摘要，限制了对其具体实验方法和直接结论的深入评估。

---

## 24. NeoPrecis：通过整合合格的免疫原性与克隆性感知的新抗原景观，增强免疫治疗反应预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577704)
**期刊：** Nature communications
**PMID：** 41577704
**DOI：** 10.1038/s41467-026-68651-6

### 第一部分 原文与翻译

**英文原标题：** NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.

> **英文摘要：**
> Despite the transformative impact of cancer immunotherapy, the need for improved patient stratification remains critical due to suboptimal response rates. While neoantigens are central to anti-tumor immunity, current metrics, such as tumor mutation burden (TMB), are limited by their neglect of immunogenicity and tumor heterogeneity. Here we present NeoPrecis, a computational framework designed to improve immunotherapy response prediction by refining neoantigen characterization across MHC-I and MHC-II pathways and by integrating tumor clonality information. NeoPrecis features an interpretable T-cell-recognition model that reveals the critical influence of MHC molecules on TCR recognition beyond mere antigen presentation. Benefit HLA alleles, identified through model-driven contribution analysis, exhibit significant predictive power for patient outcomes in immune checkpoint inhibitor treatment (melanoma: p-value = 0.04; NSCLC: p-value = 0.01). NeoPrecis, via its clonality-aware neoantigen landscape feature, improves immunotherapy response prediction in tumor types with varying prevalence of neoantigens, including heterogeneous NSCLC, which retains more subclonal neoantigens due to lower immun编辑压力. We thus propose NeoPrecis as a comprehensive evaluative framework for neoantigen assessment by incorporating both immunogenicity and tumor clonality, offering insights into the link between the collective quality of neoantigen landscapes and immunotherapy response.

> **中文摘要：**
> 尽管癌症免疫疗法具有变革性影响，但由于反应率不理想，改进患者分层仍然至关重要。虽然新抗原是抗肿瘤免疫的核心，但当前的指标，如肿瘤突变负荷（TMB），因忽视免疫原性和肿瘤异质性而存在局限。在此，我们提出NeoPrecis，这是一个旨在通过优化跨MHC-I和MHC-II通路的新抗原表征并整合肿瘤克隆性信息，来改进免疫治疗反应预测的计算框架。NeoPrecis具有一个可解释的T细胞识别模型，揭示了MHC分子对TCR识别的关键影响，其作用超越了单纯的抗原呈递。通过模型驱动的贡献分析识别出的有益HLA等位基因，在免疫检查点抑制剂治疗中对患者结局显示出显著的预测能力（黑色素瘤：p值=0.04；非小细胞肺癌：p值=0.01）。NeoPrecis通过其克隆性感知的新抗原景观特征，改善了在不同新抗原流行率的肿瘤类型（包括异质性非小细胞肺癌，由于其较低的免疫编辑压力而保留了更多的亚克隆新抗原）中的免疫治疗反应预测。因此，我们提出NeoPrecis作为一个综合性的新抗原评估框架，它整合了免疫原性和肿瘤克隆性，为新抗原景观的整体质量与免疫治疗反应之间的联系提供了见解。

### 第二部分 AI 大师评价

本研究旨在解决现有新抗原预测指标（如TMB）忽略免疫原性和肿瘤异质性的局限，提出了一个名为NeoPrecis的综合计算框架。其核心创新在于同时整合了经MHC-I/II通路表征的合格免疫原性信息与肿瘤克隆性信息，并构建了可解释的T细胞识别模型，揭示了MHC分子在TCR识别中的关键作用。研究发现，模型识别出的有益HLA等位基因对免疫检查点抑制剂疗效具有显著预测价值，且该框架尤其适用于异质性肿瘤（如NSCLC）的预测。该研究为精准免疫治疗提供了更全面的新抗原评估工具，但其预测性能仍需在更广泛的独立队列和癌种中进行前瞻性验证。

---

## 25. 表观基因组关联分析鉴定出儿童癌症幸存者中与治疗相关心脏代谢风险的DNA甲基化介导因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577698)
**期刊：** Nature communications
**PMID：** 41577698
**DOI：** 10.1038/s41467-026-68689-6

### 第一部分 原文与翻译

**英文原标题：** Epigenome-wide analysis identifies DNA methylation mediators of treatment-related cardiometabolic risk in survivors of childhood cancer.

> **英文摘要：**
> Childhood cancer survivors face increased cardiometabolic risks from cancer treatment exposures, yet mechanisms remain unclear. Here, epigenome-wide analysis identifies 1893 DNA methylation (DNAm) sites in peripheral-blood-mononuclear-cells (PBMCs) associated with at least one cardiometabolic risk factor (CMRF), including obesity (n = 1720), abnormal glucose (n = 201), hypertriglyceridemia (n = 145), hypercholesterolemia (n = 38) and hypertension (n = 34) in 2938 survivors from the St. Jude Lifetime Cohort. A core set of five DNAm sites near CPT1A and LMNA is associated with all CMRFs. Mediation analyses identify 24 sites mediating associations between treatments and CMRFs, implicating inflammatory and metabolic pathways. Notably, cg20370568, a cis-expression quantitative trait methylation site for ANTXR2, mediates 20% of the effect of body-trunk-radiotherapy on abnormal glucose. These findings suggest that prior genotoxic cancer treatments may become biologically embedded through DNAm variations that could contribute to cardiometabolic dysfunction and highlight candidate biomarkers for refining risk stratification and guiding intervention strategies in survivorship care.

> **中文摘要：**
> 儿童癌症幸存者因癌症治疗暴露而面临更高的心脏代谢风险，但其机制尚不清楚。本研究通过表观基因组关联分析，在圣裘德终身队列研究的2938名幸存者的外周血单个核细胞中，鉴定出1893个与至少一种心脏代谢风险因子相关的DNA甲基化位点，这些风险因子包括肥胖（n=1720）、血糖异常（n=201）、高甘油三酯血症（n=145）、高胆固醇血症（n=38）和高血压（n=34）。位于CPT1A和LMNA基因附近的五个核心DNA甲基化位点与所有心脏代谢风险因子均相关。中介分析鉴定出24个介导治疗与心脏代谢风险因子之间关联的位点，涉及炎症和代谢通路。值得注意的是，cg20370568是ANTXR2基因的一个顺式表达数量性状甲基化位点，它介导了20%的躯干放疗对血糖异常的影响。这些发现表明，先前的基因毒性癌症治疗可能通过DNA甲基化变异被生物性地“嵌入”，从而可能导致心脏代谢功能障碍，并突出了可用于完善风险分层和指导生存期护理干预策略的候选生物标志物。

### 第二部分 AI 大师评价

本研究旨在揭示儿童癌症幸存者治疗相关心脏代谢风险的潜在表观遗传机制。研究团队对大规模队列进行了表观基因组关联分析，系统性地鉴定了与多种心脏代谢风险因子相关的DNA甲基化位点，并创新性地运用中介分析，直接建立了“治疗-甲基化-临床表型”的因果路径证据，特别是量化了特定甲基化位点对放疗效应的介导比例。这一发现将既往观察到的临床关联推向机制层面，为理解治疗远期毒性的生物学嵌入提供了新视角，并提出了潜在的干预靶点与风险预测标志物。然而，研究主要基于外周血细胞甲基化，其与靶器官（如心脏、血管）功能失调的直接联系仍需进一步验证。

---

## 26. 剪接因子基因SF3B1的新发变异与神经发育障碍相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577671)
**期刊：** Nature communications
**PMID：** 41577671
**DOI：** 10.1038/s41467-026-68284-9

### 第一部分 原文与翻译

**英文原标题：** De novo variants in the splicing factor gene SF3B1 are associated with neurodevelopmental disorders.

> **英文摘要：**
> SF3B1 is an essential and ubiquitous splicing factor that plays a pivotal role in the early steps of pre-mRNA splicing. Recurrent somatic missense mutations in SF3B1 are frequent in cancers, but no constitutional variant has been reported so far. We describe here a cohort of 26 individuals with neurodevelopmental disorders, harbouring SF3B1 constitutional heterozygous variants that appeared mostly de novo. Patients present with a global developmental delay, associated with variable neurological and facial dysmorphic traits. A dichotomy may emerge between patients harbouring predicted loss of function (n = 9) and missense variants (n = 17), the latter being associated with a more severe and syndromic phenotype, including heart and gastrointestinal anomalies. We focused on de novo SF3B1 missense variants, which were largely distinct from those reported in cancer. Functional complementation assays show that de novo SF3B1 missense variants did not cause a loss of function of the protein. Targeted and genome-wide analysis of RNA splicing reveal that they affect canonical and alternative splicing more moderately than somatic variants, and subtly modify the splicing of many transcripts. These findings place SF3B1 among the rare U2 snRNP components implicated in both cancer and neurodevelopmental disorders, highlighting its critical and multifaceted role in human disease.

> **中文摘要：**
> SF3B1是一种必需且普遍存在的剪接因子，在前mRNA剪接的早期步骤中起着关键作用。SF3B1中的复发性体细胞错义突变在癌症中很常见，但迄今为止尚未报道过体质性变异。我们在此描述了一个由26名神经发育障碍患者组成的队列，他们携带的SF3B1体质性杂合变异大多为新发。患者表现为全面性发育迟缓，并伴有不同程度的神经和面部畸形特征。携带预测功能丧失变异（n=9）的患者与携带错义变异（n=17）的患者之间可能出现二分法，后者与更严重且具有综合征性的表型相关，包括心脏和胃肠道异常。我们重点关注了SF3B1的新发错义变异，这些变异与癌症中报道的变异有很大不同。功能互补实验表明，SF3B1新发错义变异并未导致蛋白质功能丧失。靶向和全基因组范围的RNA剪接分析揭示，与体细胞变异相比，它们对规范剪接和选择性剪接的影响更为温和，并微妙地改变了许多转录本的剪接。这些发现将SF3B1置于罕见的、同时涉及癌症和神经发育障碍的U2 snRNP组分之列，突显了其在人类疾病中关键且多方面的作用。

### 第二部分 AI 大师评价

本研究首次系统报道了剪接因子SF3B1的体质性变异与神经发育障碍（NDD）的关联，填补了该基因在非癌症疾病领域的知识空白。研究通过临床队列分析、功能互补实验及RNA剪接组学分析，揭示了新发错义变异通过一种非功能丧失的、温和影响剪接的机制致病，这与癌症中常见的体细胞突变机制不同。其创新性在于将SF3B1确立为连接癌症与NDD的罕见U2 snRNP组分，拓展了对剪接调控在发育中作用的理解。局限性在于队列样本量仍有限，且对变异导致剪接谱细微改变的具体致病通路尚需深入解析。

---

## 27. 伴侣蛋白工厂中四级结构的共翻译决定机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41577667)
**期刊：** Nature communications
**PMID：** 41577667
**DOI：** 10.1038/s41467-026-68687-8

### 第一部分 原文与翻译

**英文原标题：** Co-translational determination of quaternary structures in chaperone factories.

> **英文摘要：**
> The HSP90/R2TP quaternary chaperone assembles key cellular机器，包括三种核RNA聚合酶和许多非编码RNP。 Here, we characterize the RNAs associated with R2TP and find that it binds many proteins co-translationally. Its co-translational interactome reveals potential clients and distinguishes clients bound only co-translationally, only post-translationally, or both. For subunits assembling together in the same complex and bound co-translationally by R2TP, only a marginal proportion of their mRNAs is co-localized and co-translated. Instead, HSP90 and R2TP induce the formation of polysome condensates accumulating these chaperones and specific client mRNAs, thus favoring co-translational interactions between them. During the assembly process, R2TP cycles between co- and post-translational steps and this is regulated by ATP: it binds co-translationally in absence of ATP and becomes released from post-translational assembly intermediates by ATP hydrolysis. This co-translational mechanism, named co-translational chaperone channeling (cha-cha), substitutes for the rarity of co-localized/co-translated mRNAs. In turn, chaperones have the remarkable ability to spatially organize the translational apparatus in the cytoplasm.

> **中文摘要：**
> HSP90/R2TP四级伴侣蛋白组装关键的细胞机器，包括三种核RNA聚合酶和许多非编码RNP。在此，我们表征了与R2TP相关的RNA，并发现它共翻译地结合许多蛋白质。其共翻译相互作用组揭示了潜在的客户蛋白，并区分了仅共翻译结合、仅翻译后结合或两者兼有的客户蛋白。对于在同一复合物中组装且被R2TP共翻译结合的亚基，只有一小部分它们的mRNA是共定位和共翻译的。相反，HSP90和R2TP诱导了多聚核糖体凝聚物的形成，这些凝聚物聚集了这些伴侣蛋白和特定的客户mRNA，从而促进了它们之间的共翻译相互作用。在组装过程中，R2TP在共翻译和翻译后步骤之间循环，这一过程受ATP调控：它在缺乏ATP时共翻译结合，并通过ATP水解从翻译后组装中间体中被释放。这种共翻译机制，被命名为共翻译伴侣蛋白通道化（cha-cha），替代了共定位/共翻译mRNA的稀缺性。反过来，伴侣蛋白具有在细胞质中空间组织翻译装置的非凡能力。

### 第二部分 AI 大师评价

本研究旨在揭示HSP90/R2TP伴侣蛋白复合物在组装关键细胞机器时，如何通过一种新的共翻译机制决定其客户蛋白的四级结构。研究通过表征R2TP的共翻译相互作用组，并结合生化分析，发现该伴侣系统通过诱导形成富含特定客户mRNA的多聚核糖体凝聚物来促进共翻译相互作用，而非依赖mRNA的共定位。其核心创新在于提出了受ATP调控的“共翻译伴侣蛋白通道化（cha-cha）”模型，该模型解释了在缺乏共翻译mRNA的情况下，伴侣蛋白如何高效地组织翻译装置以完成组装。然而，该模型在活细胞中的动态细节及其普遍性仍需进一步验证。

---

## 28. DHODH：化疗耐药B细胞急性淋巴细胞白血病的一个可靶向代谢“阿喀琉斯之踵”

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576347)
**期刊：** Blood
**PMID：** 41576347
**DOI：** 10.1182/blood.2025029264

### 第一部分 原文与翻译

**英文原标题：** DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

> **英文摘要：**
> Relapse remains a major barrier to survival in B-cell acute lymphoblastic leukemia (B-ALL). Both activation of B-cell signaling pathways and increased glucose consumption have been linked to chemo-resistance and relapse risk. Here, we connect these observations, showing that B-ALL cells with active signaling, marked by high phosphorylated ribosomal protein S6 (pS6+), are glucose dependent. Isotope tracing confirms that pS6+ cells are highly glycolytic and rely on glucose for de novo nucleotide synthesis. Uridine, but not other purines or pyrimidines, rescues pS6+ cells from glucose deprivation, highlighting uridine as essential for survival. Active mTOR signaling in pS6+ cells drives de novo pyrimidine synthesis by activating CAD (Carbamoyl phosphate synthetase 2, Aspartate transcarbamylase, and Dihydroorotase), which catalyzes the first steps of de novo pyrimidine synthesis. Inhibiting signaling abolishes glucose dependency and CAD phosphorylation. Primary pS6+ cells express high levels of pyrimidine synthesis proteins, including dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in pyrimidine synthesis. Increased DHODH expression correlates with relapse and poor event-free survival. Most B-ALL molecular subtypes exhibit DHODH activity. BAY-2402234, a DHODH inhibitor, effectively kills pS6+ cells in vitro, with IC50 values correlating with pS6 signaling strength across 14 B-ALL patient-derived xenografts (PDX). In vivo, DHODH inhibition prolongs survival and reduces leukemia burden in pS6+ B-ALL models. These findings link active signaling to pyrimidine dependency and relapse risk, highlighting DHODH inhibition as a promising therapeutic strategy for chemo-resistant B-ALL.

> **中文摘要：**
> 复发仍然是B细胞急性淋巴细胞白血病（B-ALL）生存的主要障碍。B细胞信号通路的激活和葡萄糖消耗的增加都与化疗耐药和复发风险相关。在此，我们将这些观察联系起来，表明具有活跃信号（以高磷酸化核糖体蛋白S6（pS6+）为标志）的B-ALL细胞是葡萄糖依赖性的。同位素示踪证实，pS6+细胞具有高度糖酵解活性，并依赖葡萄糖进行从头核苷酸合成。尿苷（而非其他嘌呤或嘧啶）能将pS6+细胞从葡萄糖剥夺中拯救出来，这突显了尿苷对其生存至关重要。pS6+细胞中活跃的mTOR信号通过激活CAD（氨甲酰磷酸合成酶2、天冬氨酸转氨甲酰酶和二氢乳清酸酶复合体）来驱动从头嘧啶合成，CAD催化了从头嘧啶合成的最初步骤。抑制信号传导可消除葡萄糖依赖性和CAD磷酸化。原代pS6+细胞高表达嘧啶合成蛋白，包括嘧啶合成的限速酶二氢乳清酸脱氢酶（DHODH）。DHODH表达增加与复发和不良无事件生存期相关。大多数B-ALL分子亚型都表现出DHODH活性。DHODH抑制剂BAY-2402234在体外能有效杀死pS6+细胞，其IC50值与14个B-ALL患者来源异种移植瘤（PDX）中的pS6信号强度相关。在体内，抑制DHODH可延长pS6+ B-ALL模型小鼠的生存期并减轻白血病负荷。这些发现将活跃的信号传导与嘧啶依赖性和复发风险联系起来，突显了DHODH抑制是治疗化疗耐药B-ALL的一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在探索化疗耐药B-ALL的代谢弱点，核心目的是将已知的信号通路激活与葡萄糖代谢表型联系起来，并寻找可靶向的治疗策略。研究通过结合细胞表型分析、同位素示踪、分子机制探索及临床前模型验证，系统性地揭示了pS6高信号B-ALL细胞对葡萄糖的依赖源于mTOR/CAD通路驱动的从头嘧啶合成，并锁定DHODH为关键靶点。其创新性在于成功构建了“活跃信号→葡萄糖代谢重编程→嘧啶合成依赖→DHODH靶向治疗”的完整逻辑链条，并将DHODH表达与临床预后直接关联，为克服化疗耐药提供了新的代谢干预思路。局限性在于研究主要基于临床前模型，DHODH抑制剂在人体内的疗效和安全性仍需临床试验验证，且对其他耐药机制（如嘌呤代谢异常、微环境因素）的探讨相对有限。

---

## 29. 乳腺癌治疗中的机会窗口：以更少的患者、更短的时间获取更多洞见。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576319)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41576319
**DOI：** 10.1200/JCO-25-02714

### 第一部分 原文与翻译

**英文原标题：** Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题聚焦于乳腺癌治疗中的“机会窗口”概念，核心目的旨在探讨如何通过优化研究设计，在临床试验中利用更少的患者和更短的时间周期来获取更深入的生物学或疗效洞见。其方法可能涉及对术前新辅助治疗等特定治疗阶段（即“机会窗口”）的深入利用，进行密集的生物标志物采样和动态监测。其创新性在于挑战传统大规模临床试验范式，倡导更高效、更具转化价值的研究模式。然而，由于摘要不可用，具体的研究设计、数据支撑结论以及该方法的普适性和局限性尚不明确。

---

## 30. 卡铂新辅助治疗人表皮生长因子受体2阳性乳腺癌的兴衰史。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576311)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41576311
**DOI：** 10.1200/JCO-25-02855

### 第一部分 原文与翻译

**英文原标题：** Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题以历史性视角，回顾了卡铂在HER2阳性乳腺癌新辅助治疗中的应用变迁。其核心目的可能是探讨该疗法从兴起到被重新评估或替代的临床证据演变过程。方法上，推测为对相关临床试验数据的系统性回顾或荟萃分析。主要发现可能揭示了卡铂联合疗法在特定阶段的价值，以及其疗效、毒性或在新标准疗法背景下的局限性。其创新性在于提供了治疗策略演变的宏观叙事，但局限性在于摘要缺失，无法获知其具体结论与最新证据。

---

## 31. 早期剂量探索肿瘤学试验中患者报告结局研究目标的国际共识驱动推荐：OPTIMISE-ROR项目

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576310)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41576310
**DOI：** 10.1200/JCO-25-01625

### 第一部分 原文与翻译

**英文原标题：** International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.

> **英文摘要：**
> PURPOSE: There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS: Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual共识会议 (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS: Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION: This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation-ultimately contributing to the development of safer, more effective therapies.

> **中文摘要：**
> 目的：将患者报告结局（PROs）纳入早期剂量探索肿瘤学试验（DFOTs）以评估耐受性、指导剂量选择并为后期试验设计提供参考，正日益受到科学界的关注。然而，研究表明，DFOTs中的PRO研究目标常常不明确。OPTIMISE-ROR项目旨在支持试验研究者将PROs有效整合到DFOTs中。方法：采用EQUATOR网络的方法学框架，指南制定过程包括：（1）对已发表的纳入PROs的DFOTs进行方法学审查；（2）生成候选条目，并通过专家咨询进行完善；（3）进行两轮国际多利益相关方德尔菲调查（第一轮[2024年10月] N=109；第二轮[2024年12月] N=96）；（4）召开由独立主席主持的虚拟共识会议（N=31；2025年1月），由多学科国际专家审查并投票确定最终纳入的条目。结果：就六项推荐达成共识，强调三个核心PRO耐受性概念：总体副作用影响、症状性不良事件和总体健康相关生活质量。无论试验设计如何，都应考虑在剂量递增和优化试验中整合PROs以为最终剂量推荐提供信息。这些推荐强调了随时间推移和跨剂量水平分析PRO数据的重要性，将PRO研究目标定义为描述性或具有统计学效力的，并评估PRO相关终点以指导后续研究的终点选择。结论：本基础性指南概述了DFOTs中关键的PRO研究目标。通过促进PROs的系统性整合，本指南支持利用以患者为中心的证据进行疗法的耐受性和疗效评估，为剂量递增、优化和监管评价提供信息，最终有助于开发更安全、更有效的疗法。

### 第二部分 AI 大师评价

该研究通过严谨的国际共识流程，为早期肿瘤剂量探索试验中患者报告结局（PRO）的整合提供了首个系统性指导框架。其核心创新在于明确了PRO研究的三大核心耐受性概念（总体副作用影响、症状性不良事件、总体生活质量），并提出了六项具体推荐，强调将PRO数据用于剂量决策。方法学上，结合了文献回顾、德尔菲法和共识会议，确保了指南的权威性和适用性。局限性在于，作为共识性指南，其实际应用效果和在不同试验设计中的普适性尚需未来研究验证，且未详细探讨PRO数据收集与处理的具体技术挑战。

---

## 32. 紫杉烷联合曲妥珠单抗和帕妥珠单抗加或不加卡铂用于人表皮生长因子受体2阳性乳腺癌的新辅助治疗：随机非劣效性III期neoCARHP试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576297)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41576297
**DOI：** 10.1200/JCO-25-02176

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

> **英文摘要：**
> PURPOSE: The neoCARHP aimed to investigate the efficacy and safety of investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab, with carboplatin (TCbHP) or without carboplatin (THP), in stage II and III human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
> 
> METHODS: The neoCARHP was a multicenter, randomized, phase III, noninferiority study. Eligible patients were women age 18 years or older with previously untreated, stage II and III, HER2-positive invasive breast cancer. Patients were randomly assigned (1:1) to receive six 3-week cycles of TCbHP or THP. The primary end point was pathologic complete response (pCR) rate in the breast and axilla (ypT0/is ypN0) in the modified intention-to-treat (mITT) population (all randomly assigned patients receiving at least one dose of study treatment). Safety was evaluated in all patients who received any study treatment.
> 
> RESULTS: Between April 30, 2021, and August 27, 2024, 774 patients were randomly assigned and 766 were included in the mITT population (382 in THP and 384 in TCbHP). pCR was achieved in 245 (64.1% [95% CI, 59.1 to 69.0]) patients in the THP group and 253 (65.9% [60.9-70.6]) in the TCbHP group (absolute difference, -1.8% [95% CI, -8.5 to 5.0]; odds ratio, 0.93 [95% CI, 0.69 to 1.25];  = .0089). The THP group had fewer grade 3 and 4 adverse events (20.7%  34.6%) and serious adverse events (1.3%  4.7%) than the TCbHP group. The most common grade 3 and 4 adverse events with THP were neutropenia (6.8%  16.4% with TCbHP), leukopenia (5.5%  14.8%), and diarrhea (2.6%  4.2%). No treatment-associated deaths occurred.
> 
> CONCLUSION: THP provided noninferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin may be applicable in HER2-positive breast cancer.

> **中文摘要：**
> 目的：neoCARHP试验旨在研究研究者选择的紫杉烷（多西他赛、紫杉醇或白蛋白结合型紫杉醇）联合曲妥珠单抗和帕妥珠单抗，加用卡铂（TCbHP）或不加卡铂（THP），在II期和III期人表皮生长因子受体2（HER2）阳性乳腺癌中的疗效和安全性。
> 
> 方法：neoCARHP是一项多中心、随机、III期、非劣效性研究。符合条件的患者为年龄≥18岁、既往未经治疗的II期和III期HER2阳性浸润性乳腺癌女性。患者按1:1随机分配接受六个周期（每三周一次）的TCbHP或THP治疗。主要终点是改良意向治疗（mITT）人群（所有随机分配并接受至少一剂研究治疗的患者）中乳腺和腋窝的病理学完全缓解（pCR）率（ypT0/is ypN0）。安全性在所有接受任何研究治疗的患者中进行评估。
> 
> 结果：2021年4月30日至2024年8月27日期间，共774例患者被随机分配，其中766例纳入mITT人群（THP组382例，TCbHP组384例）。THP组有245例（64.1% [95% CI, 59.1 至 69.0]）患者达到pCR，TCbHP组有253例（65.9% [60.9-70.6]）（绝对差异，-1.8% [95% CI, -8.5 至 5.0]；比值比，0.93 [95% CI, 0.69 至 1.25]；P = .0089）。THP组的3/4级不良事件（20.7% 对 34.6%）和严重不良事件（1.3% 对 4.7%）发生率均低于TCbHP组。THP组最常见的3/4级不良事件为中性粒细胞减少症（6.8%，TCbHP组为16.4%）、白细胞减少症（5.5% 对 14.8%）和腹泻（2.6% 对 4.2%）。未发生治疗相关死亡。
> 
> 结论：与TCbHP相比，THP方案提供了非劣效的pCR率，并改善了耐受性。在HER2阳性乳腺癌中省略卡铂可能是可行的。

### 第二部分 AI 大师评价

本研究旨在探索在HER2阳性乳腺癌新辅助治疗中，能否在THP方案（紫杉烷+双靶向）基础上安全地省略卡铂。这是一项设计严谨的III期非劣效性随机对照试验，主要终点为pCR率。结果显示，不含卡铂的THP方案在pCR率上非劣效于含卡铂的TCbHP方案，且显著降低了3/4级不良事件和严重不良事件的发生率。其创新性在于为临床提供了去强化治疗、提升耐受性的高质量证据，但局限性在于目前仅报告了pCR这一短期终点，长期生存获益（如EFS、OS）仍需进一步随访确认。

---

## 33. 饮酒与早发性胰腺癌风险之间的阈值剂量-反应关系：一项针对韩国20-39岁年轻成年人的全国性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576296)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41576296
**DOI：** 10.1200/JCO-25-01169

### 第一部分 原文与翻译

**英文原标题：** Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

> **英文摘要：**
> PURPOSE: The incidence of young-onset pancreatic cancer has increased rapidly; however, the dose-response relationship between alcohol consumption and the risk of incident young-onset pancreatic cancer remains unclear. METHODS: A nationwide cohort of 6,263,770 individuals age 20 to 39 years who underwent national health screening in Korea between 2009 and 2012 was followed until December 2020. Heavy alcohol consumption was defined as ≥30 g/day for men and ≥16 g/day for women. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) and 95% CIs. RESULTS: A total of 1,515 cases of young-onset pancreatic cancer were identified. The cumulative incidence was consistently higher among heavy drinkers compared with nondrinkers or light-to-moderate drinkers (log-rank  < .001). Heavy alcohol consumption was significantly associated with an increased risk of young-onset pancreatic cancer (aHR, 1.19 [95% CI, 1.004 to 1.42]), whereas light-to-moderate consumption was not (aHR, 1.04 [95% CI, 0.92 to 1.17]). In addition, alcohol consumption ≥3 times per week was associated with an increased risk (aHR, 1.23 [95% CI, 1.01 to 1.51]). No significant interactions were observed across most subgroups, including age, sex, obesity, smoking status, diabetes, and pancreatitis (all  for interaction > .05), except for physical activity ( = .011). CONCLUSION: Heavy alcohol consumption was significantly associated with an increased risk of young-onset pancreatic cancer in a threshold dose-response manner. These findings suggest that early public health strategies to reduce heavy alcohol consumption among young adults may help mitigate the growing burden of young-onset pancreatic cancer.

> **中文摘要：**
> 目的：早发性胰腺癌的发病率迅速上升；然而，饮酒与早发性胰腺癌发病风险之间的剂量-反应关系仍不清楚。方法：本研究对2009年至2012年间在韩国接受国民健康检查的6,263,770名20至39岁个体组成的全国性队列进行了随访，直至2020年12月。重度饮酒定义为男性≥30克/天，女性≥16克/天。使用Cox比例风险回归模型估算调整后的风险比（aHR）及其95%置信区间。结果：共识别出1,515例早发性胰腺癌病例。与不饮酒者或轻中度饮酒者相比，重度饮酒者的累积发病率始终更高（对数秩检验P < .001）。重度饮酒与早发性胰腺癌风险增加显著相关（aHR， 1.19 [95% CI， 1.004 至 1.42]），而轻中度饮酒则无显著关联（aHR， 1.04 [95% CI， 0.92 至 1.17]）。此外，每周饮酒≥3次也与风险增加相关（aHR， 1.23 [95% CI， 1.01 至 1.51]）。在大多数亚组（包括年龄、性别、肥胖、吸烟状况、糖尿病和胰腺炎）中未观察到显著的交互作用（所有交互作用P > .05），但体力活动除外（P = .011）。结论：重度饮酒以阈值剂量-反应方式与早发性胰腺癌风险增加显著相关。这些发现表明，针对年轻人减少重度饮酒的早期公共卫生策略可能有助于减轻日益增长的早发性胰腺癌负担。

### 第二部分 AI 大师评价

本研究旨在明确饮酒与早发性胰腺癌风险之间的剂量-反应关系，填补了该领域在年轻人群中的证据空白。研究基于韩国大规模全国性队列，采用前瞻性设计，对超过620万20-39岁年轻人进行了长期随访，数据可靠性高。核心发现是，重度饮酒（而非轻中度饮酒）与早发性胰腺癌风险增加存在显著的阈值效应关联，且每周饮酒频率高（≥3次）同样增加风险，这为精准的公共卫生干预提供了直接靶点。研究的创新性在于首次在年轻成年人群中系统评估并明确了这一阈值关系，局限性在于观察性研究无法完全排除残余混杂，且饮酒数据主要基于基线自我报告，可能存在测量误差。

---

## 34. 关于L. Urbach等人研究论文《错义突变特异性转录可塑性驱动胰腺癌对细胞周期抑制剂的耐药性》的勘误。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576173)
**期刊：** Science advances
**PMID：** 41576173
**DOI：** 10.1126/sciadv.aef0961

### 第一部分 原文与翻译

**英文原标题：** Erratum for the Research Article " missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer" by L. Urbach .

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对已发表研究论文的勘误，其核心目的是对原研究中的错误进行正式更正。由于勘误本身不包含研究摘要，因此无法直接评价其研究方法、发现或创新性。此类勘误的价值在于维护科学记录的准确性和完整性，是学术出版中不可或缺的纠错机制。其局限性在于，它本身不提供新的科学内容，读者需结合原文才能理解其具体更正内容。

---

## 35. 氧化激活的纳米疗法通过增强肿瘤免疫并破坏肿瘤-神经串扰来对抗骨转移瘤和癌痛。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576171)
**期刊：** Science advances
**PMID：** 41576171
**DOI：** 10.1126/sciadv.ady1292

### 第一部分 原文与翻译

**英文原标题：** Oxidation-activated nanotherapy boosts tumor immunity and disrupts tumor-nerve crosstalk to combat bone metastases and cancer pain.

> **英文摘要：**
> Bone metastasis remains a formidable challenge in oncology due to the interdependent triad of immunosuppression, neuropathic pain, and osteolytic destruction. Current treatments fail to holistically address these pathophysiological axes. Here, we develop a reactive oxygen species (ROS)-responsive liposomal nanoplatform (LipoNCs@pGSDMB) that codelivers a polymeric stimulator of interferon genes (STING) agonist and a gasdermin B (GSDMB) plasmid for dual neuro-immune modulation. Upon tumor-selective activation in metastatic bone niches, this nanotherapy induces STING-driven immune priming and GSDMB-mediated pyroptosis, triggering potent antitumor responses. Crucially, LipoNCs@pGSDMB restore voltage-gated calcium channel (VGCC) expression in tumor cells, a prognostic biomarker identified through multiomics analysis of clinical specimens, thereby blocking calcium-dependent neurosignaling and disrupting prometastatic tumor-nerve cross-talk. In breast cancer bone metastasis models, this approach achieves 94% tumor suppression, complete pain resolution, and efficient bone restoration. By converging oxidation-responsive nanomaterial engineering, immunomodulation, and neural circuit reprogramming, this work establishes a paradigm-shifting neuroimmunotherapy platform that dismantles the self-reinforcing metastasis niche while addressing its debilitating sequelae.

> **中文摘要：**
> 骨转移瘤因其免疫抑制、神经病理性疼痛和溶骨性破坏这三个相互依存的病理轴而仍是肿瘤学领域的巨大挑战。目前的治疗未能整体性地解决这些病理生理轴。在此，我们开发了一种活性氧（ROS）响应的脂质体纳米平台（LipoNCs@pGSDMB），其共递送一种聚合干扰素基因刺激因子（STING）激动剂和gasdermin B（GSDMB）质粒，用于双重神经-免疫调节。该纳米疗法在转移性骨微环境中被肿瘤选择性激活后，诱导STING驱动的免疫启动和GSDMB介导的细胞焦亡，从而引发强大的抗肿瘤反应。至关重要的是，LipoNCs@pGSDMB恢复了肿瘤细胞中电压门控钙通道（VGCC）的表达（这是通过对临床样本进行多组学分析鉴定出的预后生物标志物），从而阻断了钙依赖性神经信号传导，并破坏了促转移的肿瘤-神经串扰。在乳腺癌骨转移模型中，该方法实现了94%的肿瘤抑制、疼痛完全缓解以及有效的骨修复。通过融合氧化响应纳米材料工程、免疫调节和神经环路重编程，这项工作建立了一个范式转换的神经免疫治疗平台，该平台在解决其致残后遗症的同时，瓦解了自我强化的转移微环境。

### 第二部分 AI 大师评价

本研究旨在开发一种新型纳米疗法，以同时解决骨转移中免疫抑制、疼痛和骨破坏三大难题。其核心创新在于构建了一个ROS响应的纳米平台，通过共递送STING激动剂和GSDMB质粒，协同激活免疫和诱导焦亡，并首次揭示了通过恢复VGCC表达来阻断肿瘤-神经串扰的新机制。该方法在动物模型中展现出卓越的肿瘤抑制、镇痛和骨修复效果，为骨转移治疗提供了一个颠覆性的“神经免疫”整合治疗范式。然而，其局限性在于临床前模型的转化潜力尚待验证，纳米药物的长期生物安全性、规模化生产及在人体复杂骨微环境中的靶向效率仍需进一步评估。

---

## 36. 类固醇依赖性代谢重编程揭示了胶质母细胞瘤的新型治疗与成像方法。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576167)
**期刊：** Science advances
**PMID：** 41576167
**DOI：** 10.1126/sciadv.adx6539

### 第一部分 原文与翻译

**英文原标题：** Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma.

> **英文摘要：**
> Steroid anti-inflammatory drugs, such as dexamethasone, are routinely used to manage brain tumor-associated edema, yet their impact on brain tumor metabolism remains understudied. Here, a metabolomic screen in naïve glioblastoma cells treated with dexamethasone revealed the accumulation of -methylnicotinamide, a nicotinamide -methyltransferase (NNMT) product, through glucocorticoid receptor activation. Using stable isotope-assisted metabolomics in patients with glioblastoma, we showed that nicotinamide conversion into -methylnicotinamide exceeds that into NAD, leading to a ~7-fold accumulation of -methylnicotinamide in tumor compared to surrounding brain tissue. In orthotopic models, NNMT activity was enhanced by dexamethasone selectively in glioblastoma tumors but not in contralateral brain. Leveraging the tumor-specific activity of NNMT, we developed a novel C-nicotinamide-based positron emission tomography (PET) approach to visualizing glioblastoma tumors. Furthermore, our findings demonstrate that the dexamethasone-induced methionine-dependent nicotinamide methylation becomes detrimental for glioblastoma when combined with a methionine-restricted diet. These results show that steroids rewire methionine and nicotinamide metabolism, enabling the development of innovative PET imaging and metabolic therapies for glioblastoma.

> **中文摘要：**
> 类固醇抗炎药，如地塞米松，常规用于控制脑肿瘤相关水肿，但它们对脑肿瘤代谢的影响仍未得到充分研究。本研究通过对地塞米松处理的初始胶质母细胞瘤细胞进行代谢组学筛选，发现通过糖皮质激素受体激活，导致了烟酰胺N-甲基转移酶（NNMT）产物——N-甲基烟酰胺的积累。利用胶质母细胞瘤患者的稳定同位素辅助代谢组学，我们发现烟酰胺向N-甲基烟酰胺的转化超过了其向NAD的转化，导致肿瘤中N-甲基烟酰胺的积累量约为周围脑组织的7倍。在原位模型中，地塞米松选择性地增强了胶质母细胞瘤肿瘤中的NNMT活性，而对侧脑组织则无此效应。利用NNMT的肿瘤特异性活性，我们开发了一种新型的基于C-烟酰胺的正电子发射断层扫描（PET）方法来可视化胶质母细胞瘤肿瘤。此外，我们的研究结果表明，当地塞米松诱导的甲硫氨酸依赖性烟酰胺甲基化与甲硫氨酸限制饮食相结合时，会对胶质母细胞瘤产生有害影响。这些结果表明，类固醇重塑了甲硫氨酸和烟酰胺的代谢，从而为开发创新的PET成像和代谢疗法治疗胶质母细胞瘤提供了可能。

### 第二部分 AI 大师评价

本研究旨在探索地塞米松对胶质母细胞瘤代谢的影响，并开发基于此发现的新型诊疗策略。核心方法是结合体外细胞代谢组学筛选、患者稳定同位素示踪代谢组学以及原位动物模型验证。研究发现，地塞米松通过激活糖皮质激素受体，特异性地增强肿瘤中NNMT的活性，导致N-甲基烟酰胺大量积累，这一代谢重编程过程为肿瘤特异性PET成像（基于C-烟酰胺）和代谢疗法（甲硫氨酸限制饮食联合地塞米松）提供了新靶点。其创新性在于将常规药物的副作用转化为诊疗优势，但局限性在于临床转化效果及联合疗法的具体机制与安全性仍需进一步研究验证。

---

## 37. CD318表达定义了一类新的人类CD8调节性T细胞亚群。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576164)
**期刊：** Science advances
**PMID：** 41576164
**DOI：** 10.1126/sciadv.adz4203

### 第一部分 原文与翻译

**英文原标题：** CD318 expression defines a novel subset of human CD8 regulatory T cells.

> **英文摘要：**
> CUB domain-containing protein 1 (CDCP1; CD318) is a surface glycoprotein known as a ligand for CD6, primarily studied in tumor immunology where it associates with poor prognosis. CD318 is expressed in myeloid dendritic cells and activated monocytes associated with immunoregulatory functions. Here, selective expression of CD318 on a subset of activated human CD8 T cells, but not CD4 T cells, is shown, defining suppressor function of this cell population. CD318 CD8 T cells exhibited reduced PD-1 and KLRG-1 expression, diminished interferon-γ and tumor necrosis factor-α production, and potent suppression of autologous CD4 and CD8 T cell activation in vitro. Notably, CD8 T cells from patients with type 1 diabetes (T1D) showed reduced CD318 induction compared with controls. Mechanistically, CD318 inhibited T cell receptor signaling independently of SHP2, while its induction required interleukin-2-dependent mTOR activation. These findings identify CD318 as a marker of human CD8 T cells with implications for immune regulation and autoimmunity.

> **中文摘要：**
> 含CUB结构域蛋白1（CDCP1；CD318）是一种表面糖蛋白，已知是CD6的配体，主要在肿瘤免疫学中研究，与不良预后相关。CD318在具有免疫调节功能的髓系树突状细胞和活化单核细胞中表达。本文发现，CD318在一部分活化的人类CD8 T细胞上选择性表达，而在CD4 T细胞上不表达，从而定义了该细胞群的抑制功能。CD318阳性CD8 T细胞表现出PD-1和KLRG-1表达降低，干扰素-γ和肿瘤坏死因子-α产生减少，并在体外能有效抑制自体的CD4和CD8 T细胞活化。值得注意的是，与对照组相比，来自1型糖尿病（T1D）患者的CD8 T细胞表现出CD318诱导减少。机制上，CD318以不依赖于SHP2的方式抑制T细胞受体信号传导，而其诱导需要白细胞介素-2依赖的mTOR活化。这些发现将CD318确立为一种人类CD8 T细胞的标志物，对免疫调节和自身免疫具有意义。

### 第二部分 AI 大师评价

本研究旨在探索CD318在人类T细胞中的表达与功能，以发现新的免疫调节细胞亚群。研究通过体外功能实验和机制分析，发现CD318在活化CD8 T细胞上的选择性表达定义了一个具有强大抑制功能的新亚群，其功能与已知的耗竭/衰老标志物不同，并揭示了其诱导依赖于IL-2/mTOR通路，而抑制功能不依赖于SHP2。创新性在于首次将CD318确立为人类CD8调节性T细胞的功能性表面标志物，并发现其在1型糖尿病患者中存在诱导缺陷，为理解自身免疫病提供了新视角。局限性在于研究主要基于体外实验，其在体内生理和病理环境中的具体作用及调控网络仍需进一步验证。

---

## 38. 通过靶向FSP1选择性破坏肿瘤内调节性T细胞的脂质过氧化物稳态以增强癌症免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576157)
**期刊：** Science advances
**PMID：** 41576157
**DOI：** 10.1126/sciadv.aea3703

### 第一部分 原文与翻译

**英文原标题：** Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity.

> **英文摘要：**
> A burgeoning approach to treating cancer is the pharmacological induction of ferroptotic cell death of tumor cells. However, the impact of disrupting antiferroptotic pathways in the broader tumor microenvironment (TME), such as in immune cells, is still undefined and may complicate treatments. Here, we show that ferroptosis suppressor protein 1 (FSP1) is critically required for regulatory T cell (T cell) resistance to ferroptosis and their immunosuppressive function within the TME. Compared to other canonical ferroptosis regulators such as GPX4 and NRF2, only FSP1 was induced upon T cell activation. Deletion of  in all T cells, or T cells specifically, enhanced tumor control by selectively disrupting T cell immunosuppression within tumors without inciting autoimmune pathology in mice. As opposed to deletion of  in all T cells, T cell deletion of  did not impair antigen-specific CD8 T cell responses. These results reveal an opportunity for targeting a regulator of ferroptosis that can not only directly target cancer cells but also simultaneously enhance anticancer immune responses without inciting autoimmunity.

> **中文摘要：**
> 一种新兴的癌症治疗方法是药理学诱导肿瘤细胞的铁死亡。然而，在更广泛的肿瘤微环境（TME）中，例如在免疫细胞内，破坏抗铁死亡途径的影响仍不明确，并可能使治疗复杂化。在此，我们证明铁死亡抑制蛋白1（FSP1）对于调节性T细胞（T细胞）抵抗铁死亡及其在TME内的免疫抑制功能至关重要。与GPX4和NRF2等其他经典铁死亡调节因子相比，只有FSP1在T细胞活化时被诱导。在所有T细胞中，或特异性在T细胞中删除FSP1，通过选择性破坏肿瘤内的T细胞免疫抑制，增强了肿瘤控制，且未在小鼠中引发自身免疫病理。与在所有T细胞中删除FSP1不同，在T细胞中删除FSP1并未损害抗原特异性CD8 T细胞反应。这些结果揭示了一个靶向铁死亡调节因子的机会，该策略不仅可以直接靶向癌细胞，还能同时增强抗癌免疫反应而不引发自身免疫。

### 第二部分 AI 大师评价

本研究旨在探索靶向铁死亡抑制蛋白FSP1对肿瘤微环境中调节性T细胞功能的影响。其核心方法是利用基因敲除技术，特异性或广泛地删除T细胞中的FSP1，以评估其对肿瘤生长和免疫反应的调控作用。研究发现，FSP1是T细胞抵抗铁死亡和维持其免疫抑制功能的关键因子，靶向它可以选择性地削弱肿瘤内T细胞的免疫抑制，从而增强抗肿瘤免疫，且不引发自身免疫或损害CD8 T细胞反应。其创新性在于将铁死亡调控从肿瘤细胞扩展到免疫细胞，并识别出FSP1作为可同时靶向肿瘤细胞和免疫抑制微环境的独特节点，但局限性在于研究主要基于小鼠模型，其临床转化潜力及在人体TME中的具体作用机制仍需进一步验证。

---

## 39. 含有Tudor结构域的蛋白TDRD3通过调控依赖性T细胞分化与功能以调节免疫耐受。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41576154)
**期刊：** Science advances
**PMID：** 41576154
**DOI：** 10.1126/sciadv.aea3960

### 第一部分 原文与翻译

**英文原标题：** TDRD3, a Tudor domain-containing protein, regulates -dependent T differentiation and function to modulate immune tolerance.

> **英文摘要：**
> Tudor domain-containing protein 3 (TDRD3) functions as a methylarginine reader that relays posttranslational arginine methylation signals to the transcriptional machinery, thereby regulating cellular functions through modulation of gene expression. Regulatory T cells (T) are pivotal for establishing and maintaining immune tolerance. In this study, we demonstrate that mice with T-specific deletion of exhibit severely impaired iT, but not thymic T, differentiation. Moreover, iT, but not thymic T, derived from these mice fail to suppress colitis in adoptive transfer models, indicating compromised inhibitory capacity. Aged -deficient mice also show spontaneous autoinflammation. Mechanistically, TDRD3 is recruited by the transcription factor FOXO1, presumably in a methylation-dependent manner, to activate expression, which is essential for T differentiation. Notably, the enforced expression of in -deficient CD4 T cells rescue both iT development and suppressive function. Collectively, our findings identify TDRD3 as a central transcriptional regulator of iT differentiation and immune homeostasis, highlighting it as a potential therapeutic target for modulating immune tolerance.

> **中文摘要：**
> 含有Tudor结构域的蛋白3（TDRD3）作为一种甲基精氨酸阅读器，将翻译后精氨酸甲基化信号传递至转录机制，从而通过调控基因表达来调节细胞功能。调节性T细胞（Treg）对于建立和维持免疫耐受至关重要。在本研究中，我们证明在Treg细胞中特异性敲除TDRD3的小鼠表现出严重受损的诱导性Treg（iTreg），而非胸腺来源Treg（tTreg）的分化。此外，来自这些小鼠的iTreg（而非tTreg）在过继转移模型中无法抑制结肠炎，表明其抑制能力受损。衰老的TDRD3缺陷小鼠也表现出自发性自身炎症。从机制上讲，TDRD3被转录因子FOXO1招募（推测以甲基化依赖的方式）来激活Foxp3的表达，而这对Treg分化至关重要。值得注意的是，在TDRD3缺陷的CD4+ T细胞中强制表达Foxp3可同时挽救iTreg的发育和抑制功能。总之，我们的研究结果确定TDRD3是iTreg分化和免疫稳态的核心转录调节因子，并强调其作为调节免疫耐受的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探究TDRD3蛋白在调节性T细胞（Treg）分化与功能中的作用及其对免疫耐受的调控机制。研究者通过构建Treg细胞特异性敲除小鼠模型，结合过继转移实验和分子机制分析，发现TDRD3特异性调控外周诱导性Treg（iTreg）而非胸腺来源Treg的分化，并揭示其通过被FOXO1招募、以甲基化依赖方式激活Foxp3表达的分子通路。该研究的创新性在于首次将TDRD3这一表观遗传阅读器定位为iTreg分化的核心转录调节因子，并证实其功能缺陷会导致自身炎症，为靶向免疫耐受的干预提供了新靶点；局限性在于摘要中未详细阐述TDRD3识别特定甲基化修饰的具体模式及其在人类疾病中的相关性，有待进一步研究。

---

## 40. 胰腺囊肿监测指南的获益与风险比较：一项微观模拟研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41575395)
**期刊：** Gastroenterology
**PMID：** 41575395
**DOI：** 10.1053/j.gastro.2025.12.008

### 第一部分 原文与翻译

**英文原标题：** Comparing Harms and Benefits of Pancreatic Cyst Surveillance Guidelines: A Microsimulation Study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在通过微观模拟模型，量化比较不同胰腺囊肿监测指南的获益（如早期癌变检出）与潜在危害（如过度诊断、并发症及成本）。该方法学创新性地将复杂的临床决策转化为可量化的风险-获益比，为指南的优化提供了数据驱动的决策支持。然而，研究的准确性高度依赖于模型输入参数的可靠性，且其结果需在真实世界临床实践中进一步验证。

---

## 41. IBEX知识库：一个促进免疫荧光成像方法采纳与发展的社区资源

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41575186)
**期刊：** eLife
**PMID：** 41575186
**DOI：** 10.7554/eLife.105737

### 第一部分 原文与翻译

**英文原标题：** The IBEX knowledge-base a community resource enabling adoption and development of immunofluorescence imaging methods.

> **英文摘要：**
> The iterative bleaching extends multiplexity (IBEX) Knowledge-Base is a central portal for researchers adopting IBEX and related 2D and 3D immunofluorescence imaging methods. The design of the Knowledge-Base is modeled after efforts in the open-source software community and includes three facets: a development platform (GitHub), static website, and service for data archiving. The Knowledge-Base facilitates the practice of open science throughout the research life cycle by providing validation data for recommended and non-recommended reagents, such as primary and secondary antibodies. In addition to reporting negative data, the Knowledge-Base empowers method adoption and evolution by providing a venue for sharing protocols, videos, datasets, software, and publications. A dedicated discussion forum fosters a sense of community among researchers while addressing questions not covered in published manuscripts. Together, scientists from around the world are advancing scientific discovery at a faster pace, reducing wasted time and effort, and instilling greater confidence in the resulting data.

> **中文摘要：**
> 迭代漂白扩展多重性（IBEX）知识库是研究人员采纳IBEX及相关2D和3D免疫荧光成像方法的核心门户。该知识库的设计借鉴了开源软件社区的努力，包含三个层面：开发平台（GitHub）、静态网站和数据归档服务。知识库通过为一抗和二抗等推荐及非推荐试剂提供验证数据，促进了开放科学实践在整个研究生命周期中的应用。除了报告阴性数据外，知识库还通过提供一个共享实验方案、视频、数据集、软件和出版物的平台，推动了方法的采纳与演进。一个专门的讨论论坛在解决已发表文献未涵盖问题的同时，培养了研究人员之间的社区意识。全球科学家正携手以更快的速度推进科学发现，减少时间和精力的浪费，并增强对所得数据的信心。

### 第二部分 AI 大师评价

本文介绍了一个名为IBEX知识库的社区资源平台，其核心目的是通过集成开发平台、静态网站和数据归档服务，系统性促进免疫荧光成像方法的采纳、优化与共享。该平台借鉴开源软件模式，创新性地整合了试剂验证数据（包括阴性结果）、实验方案、软件及社区讨论功能，旨在推动开放科学实践。其主要贡献在于构建了一个全生命周期的协作生态系统，有望显著提升方法学研究的效率和数据可靠性。然而，其实际影响力高度依赖于研究社区的持续参与和数据贡献，平台的可维护性及数据质量控制机制是其长期成功的关键潜在挑战。

---

## 42. 结肠癌细胞不对称分裂的稳健评估。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41574578)
**期刊：** eLife
**PMID：** 41574578
**DOI：** 10.7554/eLife.104528

### 第一部分 原文与翻译

**英文原标题：** Robust assessment of asymmetric division in colon cancer cells.

> **英文摘要：**
> Asymmetric partition of fate determinants during cell division is a hallmark of cell differentiation. Recent work suggested that such a mechanism is hijacked by cancer cells to increase both their phenotypic heterogeneity and plasticity and, in turn, their fitness. To quantify fluctuations in the partitioning of cellular elements, imaging-based approaches are used, whose accuracy is limited by the difficulty of detecting cell divisions. Our work addresses this gap, proposing a general method based on high-throughput flow cytometry measurements coupled with a theoretical framework. We applied our method to a panel of both normal and cancerous human colon cells, showing that different kinds of colon adenocarcinoma cells display very distinct extents of fluctuations in their cytoplasm partition, explained by an asymmetric division of their size. To test the accuracy of our population-level protocol, we directly measure the inherited fractions of cellular elements from extensive time lapses of live-cell laser scanning microscopy, finding excellent agreement across the cell types. Ultimately, our flow cytometry-based method promises to be accurate and easily applicable to a wide range of biological systems where the quantification of partition fluctuations would help account for the observed phenotypic heterogeneity and plasticity.

> **中文摘要：**
> 细胞分裂过程中命运决定因子的不对称分配是细胞分化的一个标志。近期研究表明，癌细胞会劫持这一机制以增加其表型异质性和可塑性，进而增强其适应度。为了量化细胞组分分配中的波动，通常使用基于成像的方法，但其准确性受限于检测细胞分裂的难度。我们的工作填补了这一空白，提出了一种基于高通量流式细胞术测量并结合理论框架的通用方法。我们将该方法应用于一组正常和癌变的人类结肠细胞，结果显示不同类型的结肠腺癌细胞在其细胞质分配上表现出非常不同的波动程度，这可通过其大小的不对称分裂来解释。为了验证我们群体水平方案的准确性，我们通过活细胞激光扫描显微镜的长时间延时成像直接测量了细胞组分的遗传比例，发现在不同细胞类型间具有极好的一致性。最终，我们基于流式细胞术的方法有望成为一种准确且易于应用于广泛生物系统的工具，在这些系统中，量化分配波动将有助于解释观察到的表型异质性和可塑性。

### 第二部分 AI 大师评价

本研究旨在开发一种稳健的方法来量化癌细胞的不对称分裂，以解释其表型异质性。其核心创新在于将高通量流式细胞术与理论框架结合，克服了传统成像方法在检测细胞分裂事件上的局限性。研究发现，不同类型的结肠腺癌细胞在细胞质分配波动上存在显著差异，这与其大小不对称分裂相关，并通过活细胞显微镜成像验证了方法的准确性。该方法具有通用性潜力，但其主要发现基于结肠癌细胞模型，在其他癌症类型或生物系统中的普适性仍需进一步验证。

---

## 43. 国际胰腺外科研究组（ISGPS）关于胰腺切除术后死亡的定义与分类

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41572457)
**期刊：** Annals of surgery
**PMID：** 41572457
**DOI：** 10.1097/SLA.0000000000007019

### 第一部分 原文与翻译

**英文原标题：** The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality.

> **英文摘要：**
> OBJECTIVE: The International Study Group of Pancreatic Surgery (ISGPS) aimed to uniform the definition and classification of mortality following pancreatic resections, to guide strategies for reducing preventable deaths and standardize reporting. BACKGROUND: Reported rates of mortality after pancreatic surgery vary widely depending on patient comorbidities, case mix, and institutional expertise and resources. Conventional reporting lacks granularity and fails to capture the mechanisms leading to death. A standardized classification rooted in causal analysis may provide a more meaningful framework to appraise outcomes and design targeted interventions. METHODS: A systematic review of the literature, focusing on mortality rates, causes of death, and existing classification systems after pancreatectomy was conducted. A consensus definition and tripartite classification were developed through iterative discussions, revisions, and final approval by the ISGPS board members. RESULTS: Postpancreatectomy mortality (PPM) was defined as death occurring within 90 days of any pancreatic resection, directly or indirectly attributable to a surgical complication and retrospectively linked to it through root-cause analysis. Three categories were established: PPM 1, vascular/technical complexity-related mortality (15-30%); PPM 2, pancreatectomy-specific complication-related deaths, mainly due to postoperative pancreatic fistula (POPF) and secondary systemic deterioration (45-65%); and PPM 3, cardiopulmonary and cerebrovascular deaths (10-25%). Each category reflects distinct mechanisms, timing of onset, intervention windows, and opportunities for rescue. DISCUSSION: The proposed ISGPS classification of mortality enables the development of targeted strategies to reduce potentially preventable deaths and provides a more robust framework for the appraisal and benchmarking of surgical outcomes. Prospective validation is warranted to standardize this newly defined quality metric, ensuring its consistent use in future reporting and ultimately enhancing surgical quality and patient safety on a global scale.

> **中文摘要：**
> 目的：国际胰腺外科研究组（ISGPS）旨在统一胰腺切除术后死亡的定义与分类，以指导减少可预防性死亡的策略并标准化报告。背景：胰腺手术后的死亡率报告因患者合并症、病例构成、机构专业水平和资源而异，差异很大。传统报告缺乏细节，未能捕捉导致死亡的机制。一个基于因果分析的标准化分类，可能为评估结果和设计针对性干预措施提供一个更有意义的框架。方法：对文献进行了系统回顾，重点关注胰腺切除术后的死亡率、死亡原因和现有分类系统。通过反复讨论、修订并经ISGPS董事会成员最终批准，制定了一个共识定义和三分法分类。结果：胰腺切除术后死亡率（PPM）被定义为在任何胰腺切除术后90天内发生的死亡，直接或间接归因于手术并发症，并通过根本原因分析与之关联。建立了三个类别：PPM 1，血管/技术复杂性相关死亡（15-30%）；PPM 2，胰腺切除术特异性并发症相关死亡，主要由于术后胰瘘（POPF）和继发性全身性恶化（45-65%）；以及PPM 3，心肺和脑血管死亡（10-25%）。每个类别反映了不同的机制、发生时间、干预窗口和抢救机会。讨论：所提出的ISGPS死亡率分类有助于制定针对性策略以减少潜在可预防的死亡，并为评估和比较手术结果提供了一个更稳健的框架。需要进行前瞻性验证以标准化这一新定义的质量指标，确保其在未来报告中的一致使用，并最终在全球范围内提升手术质量和患者安全。

### 第二部分 AI 大师评价

该研究旨在解决胰腺切除术后死亡率报告不一致、缺乏病因学深度的问题。其核心创新在于，通过系统回顾和专家共识，首次提出了一个基于根本原因分析、具有时间窗（90天）和病因学关联的明确定义，并建立了包含血管/技术、胰腺特异性并发症及心肺脑血管事件的三分法分类体系。这一框架超越了简单的死亡率数字，揭示了不同死亡类别的机制、干预窗口和可预防性潜力，为精准质量改进和标准化国际比较提供了有力工具。其局限性在于分类主要基于回顾性分析，其临床实用性和对不同医疗体系的普适性有待前瞻性研究验证。

---

## 44. 基于同型膜驱动的电化学微流控分析细胞外囊泡用于精准癌症诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41571694)
**期刊：** Nature communications
**PMID：** 41571694
**DOI：** 10.1038/s41467-026-68770-0

### 第一部分 原文与翻译

**英文原标题：** Homotypic membrane-powered electrochemical microfluidic analysis of extracellular vesicles for precise cancer diagnosis.

> **英文摘要：**
> The cancer cell membrane, rich in tumor-associated antigens, effectively replicates the characteristics of cancer cells by presenting specific protein profiles. Leveraging the inherent binding capability of the cancer cell membrane, here we show a homotypic membrane-powered biomimetic interface for subtype-specific analysis of breast cancer extracellular vesicles (EVs). Specifically, the breast cancer cell membrane is employed to coat a gold substrate, thereby forming the biomimetic interface capable of selectively binding breast cancer EVs with similar subtype features. Subsequently, silver nanoparticles-tethered antibodies are adopted as electroactive immunoprobes to label these EVs, generating distinct electrochemical signals for quantitative analysis. Research findings demonstrate high selectivity and sensitivity of the interface for analyzing target EVs. Based on this, an electrochemical microfluidic device is developed and validated for its effectiveness in identifying subtype features of breast cancer patients. Therefore, our work provides a simple yet efficient platform for precise cancer diagnosis and personalized treatment.

> **中文摘要：**
> 富含肿瘤相关抗原的癌细胞膜，通过呈现特定的蛋白质谱，有效复现了癌细胞的特性。利用癌细胞膜固有的结合能力，本研究展示了一种用于乳腺癌细胞外囊泡亚型特异性分析的同型膜驱动仿生界面。具体而言，采用乳腺癌细胞膜包覆金基底，从而形成能够选择性结合具有相似亚型特征的乳腺癌细胞外囊泡的仿生界面。随后，采用银纳米颗粒偶联的抗体作为电活性免疫探针来标记这些囊泡，产生独特的电化学信号用于定量分析。研究结果表明，该界面在分析目标细胞外囊泡方面具有高选择性和高灵敏度。基于此，开发了一种电化学微流控装置，并验证了其在识别乳腺癌患者亚型特征方面的有效性。因此，我们的工作为精准癌症诊断和个性化治疗提供了一个简单而高效的平台。

### 第二部分 AI 大师评价

本研究旨在开发一种用于乳腺癌精准诊断的亚型特异性细胞外囊泡分析平台。其核心创新在于利用同源癌细胞膜构建仿生界面，实现了对特定亚型细胞外囊泡的高选择性捕获，并结合银纳米颗粒标记与电化学微流控技术进行高灵敏检测。该方法将仿生识别与电化学信号放大相结合，为液体活检提供了新策略，并在患者样本中验证了其区分亚型的潜力。然而，摘要未提及该平台对其他癌症类型的普适性、大规模临床验证结果以及具体检测限等关键性能参数，其实际应用的稳健性有待进一步考察。

---

## 45. 应激囊泡将表皮机械转导与干细胞分化联系起来。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41571638)
**期刊：** Nature communications
**PMID：** 41571638
**DOI：** 10.1038/s41467-026-68294-7

### 第一部分 原文与翻译

**英文原标题：** Stress vesicles link epidermal mechanotransduction to stem cell differentiation.

> **英文摘要：**
> The skin exhibits extraordinary plasticity, enabling it to adapt to mechanical changes in the environment. While transient deformations are accommodated without lasting structural effects, sustained mechanical stress induces durable tissue changes. To investigate if these responses are mediated by shifts in epidermal stem cell fate, we employed two-photon intravital imaging to visualize epidermal cells in live skin subjected to acute mechanical forces. Mechanical force triggered the formation of intracellular "stress" vesicles within epidermal stem cells that filled with extracellular fluid and progressively enlarged, deforming the nucleus. Lineage tracing analyses revealed that the extent of nuclear deformation can predict cell fate outcomes. Moreover, mechanical stress caused sustained elevation of intracellular calcium in basal epidermal stem cells, and conditional deletion of the mechanosensitive ion channel Piezo1 disrupted calcium dynamics and increased stress vesicle formation. Using human skin xenografts, we demonstrated that stress vesicles are conserved in mammalian skin. Together, these findings identify stress vesicles as key mediators linking mechanical stress, calcium signaling, and epidermal stem cell fate.

> **中文摘要：**
> 皮肤展现出非凡的可塑性，使其能够适应环境中的机械变化。瞬时形变可以被容纳而不产生持久的结构性影响，而持续的机械应力则会诱导持久的组织改变。为了探究这些反应是否由表皮干细胞命运的改变所介导，我们采用双光子活体成像技术，对经受急性机械力的活体皮肤中的表皮细胞进行了可视化观察。机械力触发了表皮干细胞内充满细胞外液并逐渐增大、使细胞核变形的细胞内“应激”囊泡的形成。谱系追踪分析揭示，细胞核变形的程度可以预测细胞命运的结果。此外，机械应力导致基底表皮干细胞内钙离子持续升高，而条件性敲除机械敏感离子通道Piezo1会破坏钙离子动态并增加应激囊泡的形成。利用人皮肤异种移植模型，我们证明了应激囊泡在哺乳动物皮肤中是保守存在的。总之，这些发现将应激囊泡确定为连接机械应力、钙信号传导和表皮干细胞命运的关键介质。

### 第二部分 AI 大师评价

本研究旨在揭示皮肤适应机械应力的细胞机制，核心目的是探究机械力如何通过影响表皮干细胞命运导致组织重塑。研究巧妙地结合了双光子活体成像、谱系追踪、基因操作和异种移植等多种前沿技术，方法学上具有显著优势。其关键发现是鉴定出了一种新型的细胞结构——“应激囊泡”，它作为机械应力、钙信号和细胞核变形之间的物理桥梁，最终决定了干细胞的分化命运，这一发现具有重要的创新性。然而，摘要未提及应激囊泡的具体分子组成及其最终去向，这是未来研究需要阐明的重要局限性。

---

## 46. 靶向MET介导的酪氨酸激酶抑制剂耐药在EGFR突变型非小细胞肺癌中的研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544644)
**期刊：** Lancet (London, England)
**PMID：** 41544644
**DOI：** 10.1016/S0140-6736(25)02116-6

### 第一部分 原文与翻译

**英文原标题：** Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于EGFR突变型非小细胞肺癌治疗中的关键临床挑战——由MET通路异常介导的酪氨酸激酶抑制剂耐药。其核心目的旨在探索针对此耐药机制的治疗策略。鉴于摘要不可用，推测其方法可能涉及临床前模型验证或临床研究数据。其潜在发现或为验证特定MET抑制剂（单药或联合）可克服此类耐药，创新性在于直接针对明确的继发耐药驱动因素。然而，缺乏摘要信息限制了对其具体研究设计、疗效数据及潜在局限性的评估。

---

## 47. 赛沃替尼联合奥希替尼对比化疗治疗中国晚期EGFR突变阳性、MET扩增非小细胞肺癌（SACHI）：一项多中心、开放标签、3期随机对照试验的中期分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544643)
**期刊：** Lancet (London, England)
**PMID：** 41544643
**DOI：** 10.1016/S0140-6736(25)01811-2

### 第一部分 原文与翻译

**英文原标题：** Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

> **英文摘要：**
> BACKGROUND: Savolitinib combined with osimertinib is a potential novel therapy for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) harbouring MET amplification after progression on EGFR tyrosine kinase inhibitor (TKI) therapy. We aimed to evaluate the efficacy and safety of savolitinib-osimertinib versus standard of care platinum-based doublet chemotherapy in this patient population.
> 
> METHODS: SACHI was a multicentre, randomised, active-controlled, open-label, phase 3 trial conducted across 68 Chinese hospitals. Eligible adults with locally advanced or metastatic EGFR mutation-positive NSCLC and MET amplification after EGFR TKI failure were randomly assigned (1:1) to once daily oral savolitinib-osimertinib or intravenous chemotherapy (pemetrexed plus either cisplatin or carboplatin), both in 21-day cycles. Central randomisation was implemented through an interactive web-response system with stratification based on the presence of brain metastases, previous exposure to third-generation EGFR TKIs, and EGFR mutation subtype, using a mixed block-size methodology. The primary endpoint, investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours version 1.1, was tested using a hierarchical procedure: first in the third-generation EGFR TKI-naive population, and if positive, the intention-to-treat (ITT) population. Safety analysis was performed in all patients who received at least one dose of the study treatment. Interim analysis data cutoff was Aug 30, 2024. This study is registered with ClinicalTrials.gov (NCT05015608) and is complete.
> 
> FINDINGS: Between Oct 15, 2021, and Aug 30, 2024, 211 patients were enrolled, 106 were randomly assigned to savolitinib-osimertinib and 105 were randomly assigned to chemotherapy, including 137 (65%) of 211 who were third-generation EGFR TKI-naive (69 in the savolitinib-osimertinib group; 68 in the chemotherapy group). In 106 patients in the savolitinib-osimertinib group, the median age was 59·4 years (IQR 54·3-65·8), 62 (58%) were female, and 44 (42%) were male. In 105 patients in the chemotherapy group, the median age was 61·9 years (IQR 56·3-69·1), 55 (52%) were female, and 50 (48%) were male. All participants were Asian. Median PFS was significantly prolonged with savolitinib-osimertinib versus chemotherapy in the third-generation EGFR TKI-naive (9·8 months [95% CI 6·9-12·5] vs 5·4 months [4·2-6·0]; hazard ratio 0·34 [0·21-0·56]; p<0·0001) and ITT populations (8·2 months [6·9-11·2] vs 4·5 months [3·0-5·4]; 0·34 [0·23-0·49]; p<0·0001). Grade 3 or worse treatment-emergent adverse events occurred in the same proportion of patients in both groups who received the study drugs (60 [57%] of 106 patients in the savolitinib-osimertinib group and 55 [57%] of 96 patients in the chemotherapy group).
> 
> INTERPRETATION: The savolitinib-osimertinib combination improved PFS versus chemotherapy in patients with EGFR mutation-positive, MET-amplified NSCLC that had progressed on EGFR TKI therapy, while maintaining a favourable tolerability profile. This regimen offers a potential oral treatment option for this biomarker-selected population.
> 
> FUNDING: HUTCHMED and AstraZeneca.

> **中文摘要：**
> 背景：赛沃替尼联合奥希替尼是EGFR酪氨酸激酶抑制剂（TKI）治疗后进展、携带MET扩增的EGFR突变阳性非小细胞肺癌（NSCLC）患者的一种潜在新型疗法。我们旨在评估赛沃替尼-奥希替尼对比标准含铂双药化疗在该患者人群中的疗效和安全性。
> 
> 方法：SACHI是一项在中国68家医院开展的多中心、随机、阳性对照、开放标签的3期试验。符合条件的、经EGFR TKI治疗失败后出现局部晚期或转移性EGFR突变阳性NSCLC且伴有MET扩增的成年患者，被按1:1随机分配至每日一次口服赛沃替尼-奥希替尼组或静脉化疗组（培美曲塞联合顺铂或卡铂），均以21天为一个周期。通过交互式网络应答系统进行中心随机化，并根据是否存在脑转移、既往是否使用过第三代EGFR TKI以及EGFR突变亚型进行分层，采用混合区组大小方法。主要终点是根据实体瘤疗效评价标准1.1版由研究者评估的无进展生存期（PFS），采用分层程序进行检验：首先在未使用过第三代EGFR TKI的人群中，若结果为阳性，则在意向治疗（ITT）人群中检验。安全性分析在所有接受至少一剂研究治疗的患者中进行。中期分析数据截止日期为2024年8月30日。本研究已在ClinicalTrials.gov注册（NCT05015608）并已完成。
> 
> 发现：2021年10月15日至2024年8月30日期间，共入组211例患者，106例被随机分配至赛沃替尼-奥希替尼组，105例被随机分配至化疗组，其中包括211例患者中的137例（65%）未使用过第三代EGFR TKI（赛沃替尼-奥希替尼组69例；化疗组68例）。在赛沃替尼-奥希替尼组的106例患者中，中位年龄为59.4岁（IQR 54.3-65.8），62例（58%）为女性，44例（42%）为男性。在化疗组的105例患者中，中位年龄为61.9岁（IQR 56.3-69.1），55例（52%）为女性，50例（48%）为男性。所有参与者均为亚洲人。与化疗相比，赛沃替尼-奥希替尼在未使用过第三代EGFR TKI人群（9.8个月 [95% CI 6.9-12.5] 对比 5.4个月 [4.2-6.0]；风险比 0.34 [0.21-0.56]；p<0.0001）和ITT人群（8.2个月 [6.9-11.2] 对比 4.5个月 [3.0-5.4]；0.34 [0.23-0.49]；p<0.0001）中均显著延长了中位PFS。在接受研究药物治疗的患者中，两组发生3级或更严重治疗相关不良事件的患者比例相同（赛沃替尼-奥希替尼组106例患者中的60例[57%]；化疗组96例患者中的55例[57%]）。
> 
> 解读：对于经EGFR TKI治疗后进展的EGFR突变阳性、MET扩增NSCLC患者，赛沃替尼-奥希替尼联合疗法相较于化疗改善了PFS，同时保持了良好的耐受性。该方案为这一经生物标志物筛选的人群提供了一个潜在的口服治疗选择。
> 
> 资助：和记黄埔医药与阿斯利康。

### 第二部分 AI 大师评价

本研究旨在评估赛沃替尼联合奥希替尼对比标准化疗在EGFR TKI治疗失败后、伴有MET扩增的EGFR突变阳性晚期NSCLC患者中的疗效与安全性。研究采用多中心、随机、开放标签的3期试验设计，主要终点为研究者评估的PFS。中期分析结果显示，联合疗法在未使用过三代TKI及ITT人群中均显著延长了中位PFS（风险比均为0.34），且两组严重不良事件发生率相当。该研究为这一特定耐药机制人群提供了首个在3期试验中证实有效的口服靶向联合方案，具有重要的临床转化价值；局限性包括中期分析性质、开放标签设计可能引入偏倚，以及长期总生存数据和更广泛人群的疗效尚待确认。

---

## 48. 纳武利尤单抗联合顺铂和放疗对比单用顺铂和放疗用于术后高复发风险头颈部鳞状细胞癌患者的治疗（GORTEC 2018-01 NIVOPOST-OP）：一项随机、开放标签、III期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448222)
**期刊：** Lancet (London, England)
**PMID：** 41448222
**DOI：** 10.1016/S0140-6736(25)01850-1

### 第一部分 原文与翻译

**英文原标题：** Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.

> **英文摘要：**
> BACKGROUND: Postoperative cisplatin and radiotherapy is the standard of care for high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The NIVOPOST-OP trial aimed to assess the efficacy and safety of programmed death 1 blockade by nivolumab added to cisplatin and radiotherapy in this setting.
> 
> METHODS: This open-label, phase 3 trial evaluated adding nivolumab to cisplatin and radiotherapy after surgery for LA-SCCHN with high-risk pathological features. The main inclusion criteria were age 19-74 years, an Eastern Cooperative Oncology Group performance status 0-1, squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx resected with macroscopic complete resection, and at least one high-risk pathological feature: nodal extracapsular extension, microscopically positive margins, four or more cervical nodal involvements without extracapsular extension, and multiple perineural invasions. 680 participants recruited in 82 sites across six countries (France, Spain, Poland, Belgium, Greece, and Switzerland) were randomly assigned 1:1 to receive cisplatin and radiotherapy (66 Gy, cisplatin 100 mg/m intravenously once every 3 weeks, for three cycles); or nivolumab 240 mg intravenously, followed by cisplatin and radiotherapy with three cycles of concomitant nivolumab 360 mg once every 3 weeks, and six cycles of adjuvant nivolumab 480 mg once every 4 weeks. The primary endpoint was disease-free survival as per investigator assessment in the intention-to-treat population. 230 disease-free survival events (relapses or deaths) were required to detect a hazard ratio of 0·65 with 0·05 two-sided α error, with 90% power. The trial is registered at ClinicalTrials.gov (NCT03576417) and is active, but not recruiting.
> 
> FINDINGS: The 680 patients were recruited from Oct 15, 2018, to July 3, 2024. The analysis was based on 666 participants randomly assigned until the cutoff date (April 30, 2024), at which point the required number of events was reached (median follow-up 30·3 months). Disease-free survival was significantly improved with nivolumab, cisplatin, and radiotherapy versus cisplatin and radiotherapy alone, irrespective of programmed death ligand 1 expression (HR 0·76; 95% CI 0·60-0·98; stratified log-rank test p value=0·034). There was an increase in the rate of participants with treatment-related grade 4 adverse events with nivolumab, cisplatin, and radiotherapy compared with cisplatin and radiotherapy (30 [10%] of 312 vs 16 [5%] of 306). Treatment-related deaths occurred in two participants in each group.
> 
> INTERPRETATION: Nivolumab added to cisplatin and radiotherapy in high-risk resected LA-SCCHN improves disease-free survival with moderate toxic effect increase, and can be proposed as a new standard treatment.
> 
> FUNDING: Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC) and Bristol Myers Squibb.

> **中文摘要：**
> 背景：术后顺铂联合放疗是高危切除的局部晚期头颈部鳞状细胞癌（LA-SCCHN）的标准治疗方案。NIVOPOST-OP试验旨在评估在此背景下，在顺铂和放疗基础上添加程序性死亡受体1抑制剂纳武利尤单抗的疗效和安全性。
> 
> 方法：这项开放标签、III期试验评估了对于具有高危病理特征的LA-SCCHN患者，在术后治疗中于顺铂和放疗基础上添加纳武利尤单抗的效果。主要纳入标准为：年龄19-74岁，美国东部肿瘤协作组体力状态评分0-1分，口腔、口咽、喉或下咽鳞状细胞癌经肉眼完全切除，且至少具有以下一项高危病理特征：淋巴结包膜外侵犯、显微镜下切缘阳性、无包膜外侵犯的四个或更多颈部淋巴结受累、以及多处神经周围侵犯。在六个国家（法国、西班牙、波兰、比利时、希腊和瑞士）的82个中心招募的680名参与者被按1:1随机分配接受顺铂和放疗（66 Gy，顺铂100 mg/m²静脉注射，每3周一次，共三个周期）；或接受纳武利尤单抗240 mg静脉注射，随后接受顺铂和放疗，并同时给予三个周期的纳武利尤单抗360 mg（每3周一次），以及六个周期的辅助纳武利尤单抗480 mg（每4周一次）。主要终点是意向治疗人群中研究者评估的无病生存期。需要观察到230例无病生存事件（复发或死亡）以检测风险比为0.65，双侧α误差为0.05，把握度为90%。该试验已在ClinicalTrials.gov注册（NCT03576417），目前正在进行中，但已停止招募。
> 
> 结果：680名患者于2018年10月15日至2024年7月3日期间招募。分析基于截至截止日期（2024年4月30日）随机分配的666名参与者，此时已达到所需事件数（中位随访30.3个月）。无论程序性死亡配体1表达状态如何，纳武利尤单抗联合顺铂和放疗组的无病生存期均显著优于单用顺铂和放疗组（HR 0.76；95% CI 0.60-0.98；分层对数秩检验p值=0.034）。与顺铂和放疗组相比，纳武利尤单抗联合顺铂和放疗组发生治疗相关4级不良事件的参与者比例有所增加（312人中的30人[10%] vs 306人中的16人[5%]）。每组各有两名参与者发生治疗相关死亡。
> 
> 解读：在高危切除的LA-SCCHN患者中，在顺铂和放疗基础上添加纳武利尤单抗可改善无病生存期，且毒性增加程度适中，可被提议作为新的标准治疗方案。
> 
> 资助：Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC) 和百时美施贵宝。

### 第二部分 AI 大师评价

本研究是一项针对高危术后头颈部鳞癌的重要III期临床试验。其核心目的是评估在标准顺铂联合放疗方案基础上，加入免疫检查点抑制剂纳武利尤单抗的疗效与安全性。研究设计严谨，纳入了具有明确高危病理特征的患者，并采用了包含同步和辅助阶段的强化免疫治疗方案。结果显示，三联方案显著改善了无病生存期，且获益不依赖于PD-L1表达状态，这为广泛适用提供了依据。主要创新在于首次在术后辅助治疗中证实了免疫治疗联合放化疗的价值，有望改变临床实践。局限性在于目前仅报告了无病生存期数据，总生存期获益尚待观察，且联合方案带来了更高的4级不良事件发生率，需在临床应用中权衡利弊。

---

速递结束，祝您工作愉快！